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Obstructive sleep apnea (OSA) causes 
both daytime and night-time symptoms 
for the patient; in particular the more 
severe forms of OSA are also associated 
with an increased risk of cardiovascu-
lar and metabolic diseases. This thesis 
examines the evolution of mild OSA. The 
activation of low-grade inflammation, 
which is one of the mechanisms lead-
ing to abovementioned co-morbidities, 
as well as the effect of weight loss on 
inflammation are clarified in overweight 
patients with mild OSA. This study dem-
onstrated that even mild OSA should be 
actively treated to prevent progression of 
the disease. Moreover, low-grade inflam-
mation was found to be activated already 
in early stages of disease. Weight loss 
was a useful way to decrease the inflam-
matory burden.
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ABSTRACT
Obstructive sleep apnea (OSA) is a condition where there are repetitive breathing pauses
due to upper airway obstruction during sleep. It decreases the patient’s quality of life by
causing both night-time (e.g. snoring and restless sleep) and daytime symptoms (e.g.
daytime sleepiness and impaired congnitive function). Based on the frequency of breathing
pauses,  OSA  is  divided  into  mild,  moderate  or  severe  disease.  Thus  far,  the  research  has
mainly been focused on more symptomatic subjects with moderate-to-severe OSA. In
addition to immediate symptoms, these more severe forms of OSA have been observed to
have an association with cardiovascular and cerebrovascular co-morbidities and impaired
glucose metabolism. Obesity is considered as a major risk factor for all these conditions.
Low-grade inflammation has been proposed to be one underlying mechanism which
explains  the  increased  risk  of  co-morbidities  in  patients  with  OSA.  OSA,  similar  to  many
other chronic diseases, is a progressive disease. Even though mild OSA accounts for more
than half of all OSA patients, there has been a lack of studies on the early stages of OSA or
the  evolution  of  the  disease.  Moreover,  little  is  known  about  inflammation  in  mild  OSA.
Weight reduction is believed to have an impact on resolution of OSA and related metabolic
disturbances. However, the effect of weight loss on the inflammation has not previously
been studied in OSA patients.
The present work includes a retrospective and a prospective clinical study. The aims of
the retrospective study were to evaluate the objective outcome (sleep related respiratory
events; N=50 patients) and subjective outcome (symptoms; N=81 patients) after different
treatment options for mild OSA. The prospective trial assessed the impact of mild degree
OSA on circulating inflammatory biomarkers in overweight or obese patients (N=84)
compared with control patients (N=40), and whether weight loss results in changes in these
markers (N=59).
This study shows that mild OSA, if left untreated, is a progressive disease both in terms
of sleep related respiratory events and symptoms. Upper airway surgery for mild OSA in
carefully selected patients seems to reduce the risk of disease progression. Low-grade
inflammation seems to be activated already in the early stages of disease. In overweight
patients weight reduction achieved by lifestyle intervention is an effective treatment for
mild  OSA,  and  it  also  results  in  improvement  of  inflammation.  This  study  demonstrates
that even mild OSA should be actively treated to prevent progression of the disease, and to
reduce the risk for related co-morbidities.
National Library of Medical Classification: WF143, WD 210
Medical Subject Headings: Sleep Apnea, Obstructive; Obesity; Inflammation
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TIIVISTELMÄ
Obstruktiivisella uniapneataudilla tarkoitetaan ylempien hengitysteiden täydellisen tai
osittaisen tukkeutumisen aiheuttamia unenaikaisia hengityskatkoja. Tautiin liittyvät
yöaikaiset oireet, kuten kuorsaus ja levoton uni, sekä päiväaikaiset oireet, kuten
päiväväsymys ja alentunut toimintakyky, heikentävät potilaan elämänlaatua.
Hengityskatkojen määrästä riippuen tauti jaetaan lievään, keskivaikeaan tai vaikeaan
asteeseen. Yli puolella uniapneapotilaista tauti on lieväasteinen. Tästä huolimatta suurin
tieteellinen mielenkiinto on kohdistunut keskivaikeaan ja vaikeaan tautimuotoon. Näihin
liittyy myös selkeämmin lisääntynyt alttius sydän- ja verisuonisairauksille,
aivoverenkiertohäiriöille sekä heikentyneelle sokeriaineenvaihdunnalle. Lihavuus on
kaikkien näiden sairauksien vaaratekijä.  Yksi selittävä tekijä liitännäissairauksien
lisääntyneelle alttiudelle voi olla matalan tason tulehdusreaktio, jota on tutkittu hyvin
vähän lieväasteisessa obstruktiivisessa uniapneataudissa. Painonpudotuksen vaikutusta
tähän tulehdusreaktioon ei ole aiemmin tutkittu uniapneapotilailla.  Obstruktiivinen
uniapnea on monen muun pitkäaikaissairauden tavoin etenevä sairaus, mutta etenemisen
kehittymistä lievästä vaikeampiin muotoihin on tutkittu vähän.
Tutkimuskokonaisuus muodostuu retrospektiivisesta ja prospektiivisesta aineistosta.
Retrospektiivisessä osiossa selvitettiin lievän uniapneataudin vaikeusasteen muutosta
erilaisten hoitovaihtoehtojen jälkeen unirekisteröintituloksen (50 potilaalla) ja oireiden
perusteella (81 potilasta). Prospektiivisessa osiossa tutkittiin taudin vaikutusta
tulehdusmerkkiaineisiin 84 ylipainoisella potilaalla. Lisäksi arvioitiin painonpudotuksen
vaikutusta näihin merkkiaineisiin.
Tutkimustulokset tukevat olettamusta, että hoitamaton obstruktiivinen uniapneatauti on
etenevä sairaus. Valikoiduilla potilailla ylähengitysteiden kirurgia esti taudin etenemisen.
Jo lievään uniapneatautiin näyttää liittyvän elimistön tulehdusreaktion aktivoituminen.
Lisäksi havaittiin, että elämäntapamuutoksella toteutettu painonpudotus vähentää
tehokkaasti tätä tulehdusreaktiota. Tämä tutkimus osoittaa, että myös lievää
uniapneatautia tulisi hoitaa taudin etenemisen ja liitännäisairauksien riskiä lisäävän
tulehdusreaktion hillitsemiseksi.
Yleinen Suomalainen asiasanasto: uniapnea-oireyhtymä; lihavuus; tulehdus
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1 Introduction
Changes in sleep have implications for quality of life and level of functioning in everyday
life.  Obstructive  sleep  apnea  (OSA)  is  a  public  health  issue  because  up  to  one  out  of  five
adults experiences at least mild OSA (1). Mild OSA is the largest subgroup of this
condition, accounting for more than half of all OSA patients. However, previous reports
have mainly focused on those patients with moderate-to-severe OSA, because of more
severe symptoms and the more indisputable association with co-morbidities. Since OSA
may  have  a  tendency  to  progress  to  more  severe  disease  (2),  an  early  intervention  to
prevent its worsening is well-justified. However, the literature is relatively sparse regarding
the natural  progression of  mild OSA as  well  as  long-term follow-up of  therapies  on early
stages of OSA.
Recent reports have indicated that OSA is most likely a risk factor for cardiovascular
disease and mortality (3-5). The underlying mechanisms explaining the association of OSA
and atherosclerotic diseases remain incompletely understood, but it has been hypothesized
that  chronic  subclinical  inflammation  could  be  one  crucial  factor  (3,6).  Thus  far,  no  clear
consensus exists on whether the association between OSA and certain inflammatory
markers  is  causal  or  simply  reflects  confounding  by  other  underlying  factors,  mainly
excessive body fat. The vast majority of OSA patients are obese, and obesity, as such, is
regarded as a chronic inflammatory condition (7,8). Moreover, very little is known about
the  role  of  inflammation  in  early  stages  of  OSA  and  the  effect  of  weight  loss  on
inflammatory markers in patients with mild disease.
It was decided to evaluate the effectiveness of different treatment modalities on early
phases of OSA, and to assess if there is an activation of the inflammatory system similar to
the situation in more severe OSA disease. A prospective study was arranged to determine
the impact of lifestyle intervention and weight loss on mild OSA and related low-grade
inflammation.
22 Review of the literature
2.1 NORMAL SLEEP
2.1.1 Sleep
Sleep  is  more  complex  than  it  seems  at  first  glance.  It  is  “…a  state  of  immobility  with
greatly reduced responsiveness, which can be distinguished from coma or anesthesia by its
rapid reversibility” (9). The hypothalamus and brainstem are the areas which actively
regulate sleep. Sleep is regulated also by homeostatic (pressure to sleep) and circadian
systems (10). Sleep is divided into rapid eye movement (REM) sleep and non-rapid eye
movement (NREM) sleep stages based on characteristics detected
electroencephalographically, electrooculographically and electromyographically (11)
(Figure 1). The NREM sleep is further divided into so called light sleep (stages 1-2) and into
a deeper slow wave sleep (stage 3). The NREM sleep comprises the majority of total sleep
time, the REM sleep accounts for only about 20-25%. In an adult, these two subtypes of
sleep cyclically alternate during the night at about 90 minutes intervals. The REM sleep is
characterized by rememberable dreams, high brain activity, decreased muscle tone, and
increased heart rate and respiration. On the contrary, during NREM sleep, all functions in
the human body slow down.  Both REM and NREM sleep have a restorative function.
However, the exact function of the sleep stages is not resolved yet (9,12). NREM sleep
seems to have a role in energy conservation and nervous system recuperation. Rapid eye
movement sleep has an important role in brain maturation and development early in life,
and in emotional regulation throughout the whole life. It also causes periodic stimulation
and local recuperation of the brain during this phase of sleep. Sleep probably has also an
important role in memory consolidation (learning enhancement).
2.1.2 Normal ventilation process during sleep
The respiratory centre, which lies in the medulla oblongata and pons, receives and
responds to chemical (O2, CO2 and hydrogen ions) and mechanical stimuli (from lungs and
chest wall), and behavioral (brain cortex) information. The chemical information about the
partial pressure of oxygen (pO2) is sensed in the carotid and aortic bodies, and transmitted
to the medulla via the ninth cranial nerve, the glossopharyngeal nerve. The partial pressure
of CO2 (pCO2)  is  sensed  by  the  carotid  body  and  a  medullar  central  chemoreceptor.
Increases in pCO2 and hydrogen ions mainly stimulate the respiratory center directly and
this leads to a rapid increase in ventilation. The pO2 has a stimulatory effect on ventilation
usually only when pO2 is less than 7.3 kPa (normal values 11-13 kPa). In addition to
chemical control of breathing, the increased mechanical load of the respiratory system
evokes changes in breathing by means of lung stretch receptors which send information to
the medulla via the tenth cranial nerve, the vagus nerve. During wakefulness, the basic
metabolic control mechanism can be overriden by voluntary and behavioral functions. The
respiratory centre sends efferent impulses to respiratory muscles. During breathing,
efferent motor output to the upper airway musculature stiffens the upper airway walls,
thus preventing collapsing of this “tube” in response to the generation of subatmospheric
intrapleural pressure generated by the respiratory muscles. (13)
3Figure 1. Behavioral states in humans. States of waking, non-rapid eye movement sleep (NREM)
and rapid eye movement sleep (REM) have behavioral, polygraphic and psychological
manifestations. In the row labelled behavior, changes in position can occur during waking and in
concert with phase changes of the sleep cycle. Sample tracings of the three variables used to
distinguish  the  state  are  shown:  an  electromyogram  (EMG),  an  electroencephalogram  (EEG)
and electro-oculogram (EOG). The EMG tracings are highest during waking, intermediate during
NREM sleep and lowest during REM sleep. The EEG and EOG are both activated during waking
and inactivated during NREM sleep. Each sample shown is approximately 20 seconds long. The
three bottom rows describe other subjective and objective state variables. Adapted by
permission from Macmillan Publishers Ltd: Nature (Hobson J.A., 437(27):1254-1256), copyright
2005.
During sleep,  ventilation is  clearly  dependent  on the  metabolic  control  system and the
primary stimulus to ventilation during sleep is arterial pCO2. During sleep, hypoventilation
and CO2 retention, increased airway resistance, apneas and suppressed reflexes, which
protect airway patency and augment ventilatory drive in the face of increased mechanical
loads, are normal findings (14). There is a decrease in the neural input from medullary
inspiratory cells to phrenic and hypoglossal nerves resulting in decline in thoracic pumping
and increased resistance of upper airways. The response to chemical stimuli decreases in
brain. These result in CO2 retention, and a reduced response to changes in CO2 or O2 in the
body.  On  the  other  hand,  reductions  in  CO2 during sleep (because of excited ventilation)
easily results in central apnea due to unmasking of hypocapnia-dependent threshold.
Hypocapnia affects the motor input of the respiratory muscles thus predisposing to
obstructive breathing episodes during sleep. During sleep, the increased mechanical load to
ventilation (e.g. sighs) may lead to inhibition of inspiration due to the lung inflation reflex.
4Sympathetic vasoconstriction is reduced during sleep and this may lead to narrowing of the
upper airway due to vascular engorgement.
The abovementioned features are mainly occurring in NREM sleep during which
breathing is under metabolic control due to the lack of cortical control (15). REM sleep
results again in increased brain activity, and postural muscle atonia. These cause more
collapse of the upper airway, increased dependency on diaphragmatic contraction and
irregular breathing frequency, and variable and depressed response to chemical stimuli.
2.2 SLEEP APNEA
2.2.1 Historical aspects
In the literature, there are detailed descriptions of sleepy obese patients, who appear to
have suffered from a sleep apnea syndrome and/or obesity-hypoventilation syndrome. The
most famous of these sleep disordered patients in the literature is the fictional fat boy Joe in
Dickens’s book The Posthumous papers of the Pickwick club originally published in 1837
(16).  Joe was a boy who consumed great quantities of food, had a red face, constantly fell
asleep  in  any  situation  at  any  time  of  day  and  snored  loudly.  Since  then,  the  association
between obesity and breathing problems has been been widely acknowledged with
ultimate description of the Pickwickian syndrome (first published in 1956) and obesity
hypoventilation syndrome (first description in 1955) (17,18). The obesity-hypoventilation
syndrome is the combination of obesity (body mass index [BMI] >30 kg/m2), daytime
hypercapnia and nighttime hypoxemia (usually with OSA) which cannot be attributed to
an alternative neuromuscular, mechanical or metabolic reason for the hypoventilation (too
shallow or slow breathing) (19).
The first sleep recordings in Pickwickian patients were conducted in 1959 in Heidelberg,
Germany, and in the next decade it was proposed that it was the disruption of sleep and
not the CO2-retention which was responsible for the daytime sleepiness in these patients
(20). In addition, it was suspected that there might be obstruction of the airway due to
retroposition  of  the  tongue.  At  the  end  of  1960s  this  was  verified  by  the  concept  that
tracheostomy could eliminate apneic episodes (21). However, the cardinal symptoms and
characteristics of OSA were not recognized until the 1970s. In 1981, new treatment tools
namely continuous positive airway pressure (CPAP) and uvulopalatopharyngoplasty
(UPPP) were introduced (22,23). Since then, the medical knowledge and publications of the
disease, of its co-morbidities and treatment have increased widely and public awareness
continues to grow.
2.2.2 Classification
Sleep apnea is a disease characterized by episodes of airflow cessation (apnea) and airflow
reduction (hypopnea) during sleep (24). These episodes occur repeatedly throughout the
period  of  sleep.  The  severity  of  sleep  apnea  is  defined  by  the  number  of  apneas  plus
hypopneas per hour of documented sleep [apnea-hypopnea index (AHI)]. Apnea is a 90%
drop in the airflow for at least 10 seconds (11). There are several definitions of hypopnea
and thus the criteria used has an effect on resultant AHI (25). At the moment, the criteria for
a hypopnea in the American Association of Sleep Medicine scoring manual is either 30% or
greater reduction in airflow for 10 seconds associated with at least 4% drop in O2 saturation,
or drop of 50% with 3% desaturation for 10 seconds.
Sleep apnea is divided into two major subtypes (11,24). In central sleep apnea, there is no
inspiratory  effort  during  the  absent  airflow.  This  generally  results  from  instability  of
respiratory control, mainly a disturbance in the metabolic control system of ventilation,
especially the CO2 dependent (26). In obstructive sleep apnea,  the  efforts  to  inspire  are
present, but the airflow is blocked in the upper airways. If there is an initial central apnea
5followed by an obstructive component, the entity is called mixed type sleep apnea.  OSA is by
far the most common type of sleep apnea. If a patient with OSA has also symptoms, the
condition  is  called  obstructive  sleep  apnea  syndrome  (OSAS).  In  one  study,  OSAS
comprised 84%, mixed sleep apnea 15% and central sleep apnea a mere 0.4% all patients
seeking help from the sleep clinic during one month (27).
OSAS is a condition that must be classified on a physiological basis [amount of apneas
and hypopneas, and arterial oxyhemoglobin saturation as measured by pulse oximeter
(SaO2) during sleep] and on an evaluation of symptoms, especially sleepiness (28,29). Table
1 provides the diagnostic criteria for OSAS. The mildest form of OSAS is defined by AHI 5-
14.9 events per hour, moderate sleep apnea as 15-29.9 events/hour, and severe as
respiratory events of 30 or more events per hour (30). If the patient has disabling daytime
sleepiness, OSAS falls into a higher category. Moreover, SaO2 should be 85% and mean
SaO2 90% in mild degree sleep apnea. In clinical practice, these criteria are further
modified by age-, gender- and individual-related changes in these parameters, clinical
status and co-morbidities.
Partial upper airway obstruction, which on the other hand is related to term upper
airway resistance syndrome (UARS), is closely related to OSA. This entity is characterized
by increased upper airway resistance with inspiratory flow limitation but without apneas,
hypopneas or desaturation (31,32). However, these episodes of partial airway obstruction
are common in both genders, especially in women, and are frequently associated with
younger age and symptoms similar to OSA (33,34).
Table 1. The diagnostic criteria for adult obstructive sleep apnea syndrome (OSAS) (24)
Minimal criteria for OSAS: A, B and D or C and D
A. At least one of the following symptoms
Unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue,
or insomnia
Waking with breath holding, gasping or choking
Loud snoring and/or breathing interruptions during sleep
B. Polysomnographic monitoring demonstrates
Five or more apneas, hypopneas or respiratory effort related arousals per hour of sleep
Respiratory effort during these respiratory events
C. Polysomnographic monitoring demonstrates
Fifteen or more apneas, hypopneas or respiratory effort related arousals per hour of sleep
Respiratory effort during these respiratory events.
D. The disorder is not explained by another sleep disorder, medical or neurological disorder, medication or
substance use.
2.2.3 Diagnostic Methods
Diagnosis  and  treatment  decisions  of  OSAS  are  based  on  symptoms  and  signs,  clinical
findings, sleep recording and sometimes imaging. Under-recognition and under-diagnosis
of this disorder are very common: it has been estimated that up to 90% of OSA cases remain
undetected and even fewer receive treatment for OSA (35-37). Especially women and those
with low BMI or with mild OSA are at risk of remaining undiagnosed and untreated.
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Subjects  with  OSA  experience  both  nocturnal  and  daytime  symptoms  (24,29).   Nocturnal
symptoms include snoring, breathing pauses, restlessness, choking, nocturia, heart burn
and sleep fragmentation. Upon awakening, the mouth may be dry, headache ensues and
the individual feels unrefreshed. Snoring, which according to Merriam-Webster Dictionary
means “to breathe during sleep with a rough hoarse noise due to vibration of the soft
palate”,  is  the  most  obvious  and  frequent  symptom  of  OSA  occurring  in  almost  all  OSA
patients  (38).  Habitual  snorers  are  more  likely  to  have  AHI  scores  15  or  higher  (39),  and
snoring intensity correlates with the severity of OSA (40). Snoring is socially disturbing and
a common cause for OSA patients to sleep in separate bedrooms from their partners.
During daytime, OSA patients may experience excessive daytime sleepiness (EDS)
(24,29). This cardinal symptom of OSAS may reflect the number of apneas: the higher AHI,
the sleepier the subject is during daytime (41). However, this may not always be the case.
Moreover,  even  simple  snoring  and  mild  OSA  associate  with  daytime  sleepiness  as
compared to the non-OSA population (39,42). The problem with EDS, and other daytime
symptoms is that they may be contributed to many other conditions from depression to the
arrival of a new baby.
In addition, inefficiency or deficits in cognitive and behavioural functions, in general
health status and quality of life are found in sleep apnea patients (43-47). Usually the
severity of OSA has an effect on these functions: patients with mild disease do not differ
from normal controls (with the exception of quality of life) but those with more severe
disease do display differences. The possible mechanisms leading to these deficits include
daytime sleepiness, comorbid diseases, as well as sleep disruption due to arousals and
hypoxemia (45,48).
Many screening tools, i.e. questionnaires, have been developed for detecting the
abovementioned symptoms in adults. These can be time-consuming, but do offer the
clinician a compact package of information on symptoms and quality of life.  They are also
a good tool for scientific purposes. The most widely used questionnaire on daytime
sleepiness is the Epworth Sleepiness Scale (ESS) (49). The objective tests of sleepiness and
vigilance – e.g. Multiple Sleep Latency Test (50) and Oxford Sleep Resistance test (51) – are
time consuming and not widely utilized in the diagnosis of OSA. There are also self-report
tools, such as the Berlin questionnaire and Snore Outcomes Survey, which focus on a set of
symptoms and clinical features associated with sleep apnea (52,53).
Clinical findings
Even  if  there  is  a  consensus  that  upper  airway  (UA)  narrowing  is  a  risk  for  OSA,  the
scientific evidence of the clinical findings predicting the presence of OSA have been found
to be unreliable (54). However, it has been shown that BMI and neck circumference
significantly correlate with AHI (55). Since the accuracy of BMI as a descriptor of obesity is
limited (56,57), waist circumference or total body fat percentage may well be better
measures, especially when estimating the risk for OSA related co-morbidities. The presence
of skeletal abnormalities (e.g. high arched palate and retropositioned mandible) and
voluminous soft tissues (large tongue and tonsils, prominent palate or uvula, and
voluminous pharyngeal walls) could also be evaluated when searching for candidates for
sleep recording (54,58). Alleviation of nasal obstruction may improve sleep quality and ease
the use of CPAP (59,60). Thus, clinical examination is important to support therapeutic
strategies and to indicate a need for a specific treatment, for example septoplasty or
tonsillectomy.
None of symptoms or signs alone is sensitive or specific enough for detecting OSA, and
there is a large spread of “typical” OSA findings within the general population. For
example,  even  though  habitual  snorers  are  more  likely  to  have  OSA,  snoring  alone  has  a
poor predictive value for the high prevalence of snoring in the general population (37,39,61-
763).  On the other hand, in subjects with no sleep related symptoms, OSA can be found in
about 3% of the subjects. However, simultaneous snoring, EDS and observed apneas
combined with well known risk factors – male sex, age and obesity - should give rise to the
suspicion of OSA. The sensitivity and specificity of the physician’s subjective impression of
the presence of OSA in a patient is about 60% (64).
Sleep recording
Thus,  on  the  basis  of  symptoms  and  clinical  findings,  the  presence  of  OSA  may  be
suspected  but  the  diagnosis  is  always  confirmed  by  overnight  recording  during  which
sleep, respiratory effort, cardiovascular signals and muscle movement – or at least some of
these parameters – are monitored. Full overnight polysomnography (PSG) recording in a
sleep laboratory is the gold standard diagnostic tool for patients with suspected sleep
apnea (30,65). Polysomnography includes measurements of at least oronasal airflow, chest
and abdominal movements, electroencephalography, electro-oculography,
electromyography, electrocardiography, oxyhemoglobin saturation, body position and
movement, and behavior (65). Due to the high cost, demands on facilities and limited
availability of full PSG, portable monitoring has become the most common diagnostic tool
for  OSA  in  Finland.   These  machines  range  from  un-attended  full  PSG  to  single  channel
recordings. However, a practicable portable monitor should, at minimum, record airflow,
respiratory effort and blood oxygenation (30). There are limitations associated with these
portable monitors (66). They are recommended for patients with a high probability of OSA
who do not have co-morbidities or any probable other sleep disorder. Moreover, assistance
with sensors is needed. Finally, the analysis of raw data should be performed according to
current standards by a trained person who is aware of the methodological limitations.
2.2.4 Epidemiology
Prevalence
Population-based studies have found that in working age population, the prevalence of
OSA is high, 4% of men and 2% of women have at least mild OSA with daytime symptoms
(39,67-70) The numbers are much higher if the daytime symptoms are ignored and only the
AHIs are considered: then the prevalences are 24-26% for men and 9-28% for women
(39,63). In Finland, there are approximately 150 000 OSA patients, of whom 85 000 have a
mild, 50 000 a moderate and 15 000 a severe form of the disease (71).
Incidence
There are very few data on the incidence of sleep disordered breathing. Tishler et al
concluded that the 5-year incidence is about 10% for AHI 15 and 16% for AHI10 (72).
Newman et all reported an incidence of moderate sleep apnea (AHI >15/h) as 11% for men
and five percent for women during a 5 year follow-up (73).
Natural evolution of OSA
Several studies have evaluated the course of OSA over time, but the data are conflicting. In
the early 80’s, a proposition of an orderly progression from snoring to OSA was published
(74).  Since  then,  many  studies  have  reported  a  progression  in  OSA  over  time  in  those
patients who initially have had only mild-to-moderate or no disease at all (2,43,73,75-81).
However, there are also a number of clinical longitudinal trials which state that AHI does
not increase over time in untreated OSA patients (82-86).
8The  predictors  for  changes  in  sleep-disordered  breathing  are  not  fully  clear  at  present
(2,72,73,77,80-82,84-86). It seems possible that increase in sleep related respiratory
disturbance indices could occur primarily before old age, if it is going to happen at all. On
the other hand, OSA in elderly people is likely to be different from the disorder in younger
subjects: changes in bony structures, in neural- and neuromuscular control, increased
diseases affecting breathing control, and changes in fat deposition probably influence the
OSA likelihood (87). The deteriorating trend of OSA has been less clear in patients with
high AHI at baseline. Moreover, change in body weight has been a significant predictor for
AHI change (39,61,63,67,69,70,72,73,80,88). For example, Peppard et al. have reported that
patients with mild OSAS have a 6-fold increase in risk for developing more severe disease if
they gain 10% of their body weight.  On the other hand, there are many smaller and older
studies, which have not found any correlation between changes in body size and changes in
sleep disordered breathing (76-78,83,86). Another possible explanation for disease
progression has been upper airway trauma, which is caused by repeated apneas and
snoring, see later in chapter “Pathogenesis”.
2.2.5 Risk factors
Some  degree  of  UA  narrowing  at  the  onset  of  sleep  is  a  normal  phenomenon  (89),  but
various  factors  may  conspire  to  accentuate  it,  such  as  obesity,  soft  tissue  (e.g.  tonsils)
enlargement and craniofacial abnormalities. The extent of this narrowing varies from
individual  to  individual,  and  from  night  to  night,  to  some  extent.  However,  it  is  well
established that occluding features in the hard and soft tissues of the UA are risk factors for
OSA.
Obesity
Obesity is an important risk factor for OSA, and it is increasingly prevalent around the
world: 72% of adult men and 64% of women are overweight or obese in the USA (BMI 25
kg/m2), and the corresponding figures for Finland are 66% for men and 53% for women
(39,67,90,91). Some 60-90% of adults with OSA are overweight, and the relative risk for
OSA in obesity is 10. Accordingly, the prevalence of OSA among obese patients has been
reported to be as high as 30-98% (7). As mentioned above, it seems that weight gain not
only  increases  the  chance  of  developing  OSA  but  it  can  also  worsen  the  severity  of  a
previously milder disease. Moreover, OSA may predispose to obesity. The possible
underlying factors for this may include increased appetite caused by resistance to leptin
and insulin (two hormones which inhibit eating and thus regulate body weight) and
increased concentrations of ghrelin (appetite increasing hormone), all of which have been
described in sleep apneics (7).
The location of fat may also be an important factor: excess fat have been reposted
around the UA in both obese and non-obese patients with OSA (92), and neck
circumference is a predictor of night-time desaturations (93). The total body fat distribution
is also a factor with the central/visceral distribution appearing hazardous (61,94). Exercise
has a protective effect against developing OSA (95).
Anatomical risk factors
Even though obesity is very common among sleep apnea patients, there are also a number
of lean people who suffer from OSA and, on the other hand, obese subjects with no OSA.
Why do some people develop collapse of UA sufficient to lead to apneas and others with
similar body sizes do not? One factor may be an anatomically small pharynx which seems
to predispose to upper airway collapse (7,96-98) (Figure 2).
9Figure 2. Schematic  explanations  for  the  mechanical  model  of  the  pharyngeal  airway  –
combination of the bony framework and amount of soft tissue. Reprinted with permission from
the  American  Thoracic  Society.  Copyright  ©  American  Thoracic  Society.  Watanabe,  Isono,
Takana et  al,  2002: Contribution of  body habitus and craniofacial  characteristics to segmental
closing pressures of the passive pharynx in patients with sleep-disordered breathing. American
Journal of Respiratory and Critical Care Medicine, Vol 165(2), pp 260-265. Official Journal of the
American Thoracic Society.
The volume of UA soft tissue structures is enlarged in patients with sleep apnea (e.g. large
tongue, tonsillar or adenoidal hypertrophy and volume of lateral walls of the pharynx).
This is attributable not only to excess fat but also to inherited factors (99). Blood
engorgement and edema around the UA lumen may also play a role. The causal factor for
UA  obstruction  may  also  be  in  the  craniofacial  morphology  i.e.  bony  framework  of  UAs
(100-103). Malocclusal traits as an indicator for mismatch between jaws, and low hyoid
bone position have been shown to predispose to OSA. Moreover, in obese individuals, the
risk of airway collapse is further elevated due to smaller airway cross-sectional area (larger
soft tissues surrounding the upper airway, reduced upper airway size secondary to mass
effect of the large abdomen, and decreased chest wall and tracheal traction) and a change in
its shape to becoming more oval (the more anterior-posterior orientation of the long axis of
the pharynx) (7).
Sex
The  prevalence  of  OSA  in  women  is  less  than  in  men,  male-female  ratio  being  about  3:1
(39,63,67,69,70). Pharyngeal anatomy may be one explanation: men have a longer airway
length and a larger but more collapsible pharyngeal airway (104). The difference in
prevalence  is  particularly  clear  when  comparing  premenopausal  women  to  men,  since  in
elderly women the prevalence of OSA increases (34,67,72,105). Female hormones augment
pharyngeal muscle activity (106) and after menopause, hormone replacement therapy can
have a protective effect against the development of OSA (67,107).
Age
The prevalence of sleep apnea increases with age (39,63,67,69,70,88,105). There is evidence
that this trend declines after approximately 65 years of age. The peak prevalence is at about
10
55 years for men and about 10 years later for women. Weight loss with age or the
underrepresentation of older age groups in the OSA study population may also be two
reasons for this finding. On the other hand, the severity of OSAS may be milder in the
elderly, at least in men.
Other risk factors
Alcohol ingestion reduces the activity of genioglossus and other dilator muscles that
maintain the patency of upper airway (108,109). In addition, the elevation of arousal
threshold and the response to chemical control of breathing may be factors contributing to
the increased risk of OSA in many conditions. For example endocrinological abnormalities
(e.g. hypothyreosis and polycystic ovarios) may increase apneic events (110,111). There are
also  studies  showing  sedating  medications  and  smoking  to  be  risk  factors  for  OSA  (112-
114).
Heritability
It has been claimed that OSA aggregates in families (115). The risk of OSA may be 2-4-fold
greater in relatives of OSA subjects when compared to controls and about 40% of AHI
variance may be explained by familial factors. Symptoms of OSA and AHI levels aggregate
in families independent of other important risk factors (e.g. BMI), and family-based
interactions  of  physiological  and  anatomical  abnormalities  may  partly  account  for  this
association. Both upper airway soft tissue and bony framework characteristics have been
demonstrated to aggregate in families (99,116,117). Similarly, there is evidence, mainly from
animal studies, that genetic factors can influence the expression (e.g. ventilatory control
patterns) and sequalae of OSA (118). However, the genetic background of OSA is largely
unknown at present.
2.2.6 Pathogenesis
The basic mechanism responsible for apnea-hypopnea events is the collapse of UA which
occurs repeatedly during sleep (Figure 3) (96). These episodes lead to hypoxia and
hypercapnia, which cause a stress reaction in the body, and increased ventilatory effort
against an occluded airway. Ultimately, arousal from sleep occurs, which restores the
airway and ventilation. Then the individual returns to sleep, but the cycle begins again.
These arousals lead to sleep fragmentation, they cause changes in sleep architecture and
thus result in lighter and non-restorative sleep (119,120).
A. B.
Figure 3. Normal (A) and obstructed (B) upper airway during sleep
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The upper airways consist of the nose, pharynx, larynx and extrathoracic trachea, of
which the pharynx is the collapsible segment.  The cross-sectional area of the UA is
determined not only by hereditary and acquired factors but also by static (surface adhesive
forces, neck and jaw posture, tracheal tug and gravity) and dynamic forces (upstream
resistance, Bernouli effect and dynamic compliance). These dynamic counteracting forces
include the activity of the upper airway muscles which stiffen and dilate the airway, the
negative  intraluminal  pressure  caused  by  thoracic  inspiratory  muscles,  and  transmural
pressure (difference between intraluminal pressure and pressure of surrounding tissues)
(98).  The muscle activity is modulated by proprioceptive and chemical feedback: the
activity of UA muscles is normally increased as the negative pressure in the lumen
increases, and by hypoxia or hypercapnia (121-124).
At sleep onset, the neural output to UA muscles and thence the muscle activity falls and
the airway lumen becomes prone to suffer occlusion (125). This instability of respiratory
control (loss of cortical control and waking neural drive and rise of stimulating metabolic
threshold) is one of the three pathophysiological characteristics in OSA (98). It has been
shown that local anaesthesia (or maybe afferent denervation in OSA) of pharynx and
repetitive intermittent hypoxia (such as in OSA) can lead to suppression of these
proprioceptive and chemical dependent reflexes, which partly guarantee the patency of the
UA. The other two mechanisms causing the apneas and hypopneas are failure to stabilize
the UA in an appropriate manner (see the previous paragraph) and disorders of the
respiratory pumps. Interestingly, there is an increased dilator muscle activation to keep the
pharynx open in OSA patients during awake periods but this is attenuated at the initiation
of sleep (126). Moreover, airway collapses are opposed by hyperactivation of pharyngeal
dilator muscles. During normal sleep or general anaesthesia, the OSA patient’s pharynx
collapses without negative pressure in contrast to normal controls who need negative
pressure  (suction)  for  this  to  happen  (127).  Usually  this  UA  narrowing  is  multilevel,  the
retropalatal region being the most common site to become obstructed (125,128).
Due to swings in intraluminal pharyngeal pressure, there are tissue vibration and violent
eccentric muscle contractions against an occluded airway and thus UA tissues are subjected
to  mechanical  trauma.  The  increased  activity  level  may  lead  to  adaptive  changes  in  both
structure and function of muscles (129). These adaptive changes may crate a vicious cycle,
promoting further compromise of the upper airway via more occluding soft tissues,
increased injury and reparative attempts (blood engorgement, edema, fibrosis,
inflammation). These changes are more pronounced in severe degree OSA (130). Moreover,
inflammatory cells and pro-inflammatory mediators may provoke muscle weakness
(131,132). If this affects also the pharyngeal muscles, then inflammation would predispose
to airway collapse. Denervation and inflammation has been found both in UA mucosa and
muscle (133). This harmful effect of inflammation (along with mechanical load) has been
proposed as a mechanism for increased risk of OSA in obese individuals: obesity is an
inflammatory condition (134). Increasing age predisposes the individual to pharyngeal
collapse (135).
2.2.7 Treatment
Treatment of OSA is aimed at reducing the collapsibility of UA during sleep by overcoming
the imbalance of forces acting on the UA. In general, the treatment modalities are intended
to a) raise the pharyngeal pressure above the closing pressure, b) decrease the closing
pressure or c) increase the upper airway muscle activity (128). The methods include
lifestyle modification, continuous positive airway pressure (CPAP), oral appliances (OAs)
and surgical options. The choice between the different modalities of treatment depends on
the patient, the predisposing factors for OSA and the severity of the disease. Multiple
interventions may be appropriate in some patients.
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Lifestyle modification
Sleep hygiene and behavior  which worsen OSA should be  checked in  every OSA patient,
and recommendations how to improve these should be offered. For example, sleep
deprivation and sleep fragmentation (24/7 society, young children at home), inebriation,
smoking and use of sedatives may increase apnoeic episodes (43,112,119,136). For patients
with supine position dependent OSA, positional therapy (e.g. a backpack with a ball inside
to  prevent  supine  sleeping)  can  provide  some  help  in  terms  of  improving  AHI,  sleep
quality and daytime symptoms (137-139). However, CPAP is superior to positional therapy
in decreasing AHI and desaturation level (138). There are no reports on the long term
efficacy of positional treatment or on its impact on co-morbidities. This treatment modality
could be considered as benefitting those mild degree OSA patients who have positional
disease.
There  have  been  some  publications  about  how  to  strengthen  upper  airway  muscles  in
order to decrease apneic episodes during sleep (140). The methods have included electrical
neurostimulation, didgeridoo playing and oropharyngeal exercises. These may have some
benefit but the evidence is very vaque.
Since obesity is the major predisposing factor for OSA, it is tempting to assume that
weight loss should be recommended for all overweight patients with OSA. In general, the
first  line  therapy  for  overweight  and  obesity  is  behavioral:  lifestyle  intervention  with
weight reduction (141). This can be augmented by special diets, medication or bariatric
surgery. The beneficial effects of dietary weight loss on OSA, sleep architecture and
daytime somnolence have been known for decades (142). However, only three well
executed studies have assessed the impact of a behavioral method to achieve weight loss,
the study by Tuomilehto et al. being the one which resulted in the present thesis (143-147).
In the study populations of overweight or obese OSA patients, these papers have indicated
that intensive supervised lifestyle intervention is more effective than general lifestyle and
diet  counselling  in  terms  of  treatment  success.  In  the  mild  sleep  apneics  in  the  study  of
Tuomilehto et al., two thirds of patients in the intervention group were objectively cured of
OSA, i.e. AHI<5, the figure for control group being only one in three. In the report of Foster
and co-workers, remission of OSA was three times more common in the intensive lifestyle
intervention group compared to the control group. Johansson et al. reported that at one
year, 10 % of mostly mild-to-moderate degree OSA patients had been cured and 48% no
longer needed CPAP. All of the abovementioned studies support the contention that the
greater the weight loss, the greater the reduction of AHI. For example, in the Swedish
report it was found that a 10 kg weight loss was associated with an average decrease of five
events/hour in the AHI. This is confirmation of earlier studies, e.g. the meta-analysis by
Greenburg and co-workers in which a mean 17.9 kg/m2 decrease in BMI achieved by
bariatric surgery resulted in mean AHI decrease by 71 % (43,148). However, weight loss
does not result in a decline in AHI to the same proportion that weight gain elevates AHI:
10% weight loss/26% fall in AHI versus 10% weight gain/32% increase in AHI (80).
Maintaining the achieved weight after dietary counselled weight loss is very challenging
(149). However, in the studies by Tuomilehto, Foster and Johansson, the improvements in
AHI were still sustained at 1-2 year(s). This beneficial effect of lifestyle intervention on OSA
may persist in spite of weight gain (Figure 4) (146). There are recent findings to suggest that
in patients with OSA, about 50% of the overall response to weight loss may be related to a
reduction in fat and in passive mechanical properties (150). The remaining half seems to be
attributable to concomitant improvement in neuromuscular properties.
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Figure 4. Mean changes in weight and in the apnea-hypopnea index (AHI) achieved by lifestyle
and dietary intervention compared with usual weight loss attempt over the 24-mo follow-up
period. A study among overweight or obese patients with mild obstructive sleep apnea. Vertical
bars indicate 95% CIs. Reprinted with permission by American Society of Nutrition. Tuomilehto
et al., The American Journal of Clinical Nutrition 2010;92(4):688-96.
While  weight  loss  can  lead  to  substancial  decreases  in  OSA  severity,  it  often  does  not
eliminate the disease altogether (43). Particularly, this is evident among patients with
severe degree of OSA (144,148). Thus it is important to remember to perform the follow-up
sleep study, and offer alternative treatment options when needed. However, CPAP
treatment does not improve the results of weight loss program which supports the use of
weight reduction as an initial treatment for obese patients with mild disease, who are
motivated to lose weight (151). There is some evidence that OSA related daytime sleepiness
decreases and quality of life increases by lifestyle intervention (143,145,147).
CPAP
Continuous positive airway pressure is the cornerstone of OSA treatment.  It  prevents UA
obstruction by delivering a stream of compressed air (produced by a flow generator) via a
hose to an interface (usually a nose mask) and this air pressure acts as a pneumatic splint to
prevent collapse of the pharyngeal airway (22). This treatment modality reduces sleepiness
and improves quality of life (152). Treatment with positive airway pressure reverses the
negative cardiovascular consequences of OSA: it improves control of hypertension (152),
reduces the risk of fatal and nonfatal cardiovascular events (4), reduces heart rate (153) and
night-time bradyarrhythmias (154), improves vascular dysfunction (155), and early signs of
atherosclerosis (156), and in patients with heart failure, it improves cardiac systolic function
(157). The evidence for the effectiveness of the CPAP is stronger in symptomatic and/or
moderate-to-severe AHI (152,158). In patients with mild-to-moderate sleep apnea, CPAP
has improved snoring and subjective daytime sleepiness (159,160). However, regardless of
the disease degree, The American Association of Sleep Medicine guideline states that CPAP
is  the  treatment  of  choice  for  OSA  (30).  CPAP  is  long-term  treatment  that  requires
compliance. However, CPAP compliance is not optimal (65-80%), and use per night can be
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suboptimal (161). Side-effects of this treatment option include leaks, skin problems, dry
upper airway, stuffy nose, rhinorrhea, claustrophobia and inconvenience with CPAP (162).
Thence, alternative treatment modalities have been developed.
Oral appliances
Madibular advancement devices increase the phayngeal space by protruding the mandible
and advancing tongue. They increase airway size in the retroglossal region as well as in the
retropalatal area, predominantly in the lateral dimension (163,164). A Cochrane report
recommended oral appliance (OA) therapy for patients with mild symptomatic OSA, and
those patients who are unwilling or unable to tolerate CPAP therapy (165). Even though
this treatment modality alleviates symptoms and respiratory disturbances, CPAP is more
effective in improving respiratory indices (165). The authors also concluded that after 1-
year, OA is as good as corrective upper airway surgery in improving symptoms, and better
than  surgery  at  reducing  AHI.  The  side-effects  of  OAs  include  jaw  and  teeth  discomfort,
salivation and occasionally joint discomfort.
Surgery
Surgery for OSA aims to relieve obstruction by increasing the size of the airway, bypassing
the obstruction or removing an obstructing lesion. There are three major anatomic regions
of potential UA obstruction: nose, palate and base of tongue (166).  Surgery can involve soft
tissues (soft palate, tonsils, tongue base), skeletal framework or it can consist of
tracheostomy. In children, adenotonsilectomy is the first line treatment and highly effective
for small and/or normal weight children (167,168).
At present, indications for surgery in adults include OSA which is not better treatable by
other options or there has been a failure with other options, and there is an anatomic
airway abnormality. Contraindications include morbid obesity, severe unstable illness,
older age and unrealistic expectations of outcome (166). The fact that the majority of OSA
patients have multilevel obstruction of UA (125,128) means that the curing effect of a single
operation is highly questionable. There have been suggestions that multilevel surgery
should be performed when needed (169).  However, the scientific evidence for this claim is
based mainly on single procedures, and current knowledge from randomised controlled
studies does not support the widespread use of surgery in adults with OSA (170). However,
the treatment response may vary from patient to patient depending on the obstruction, and
carefully selected patients may benefit from a procedure.  In the United States of America,
less than 0.2% of the adults with OSA undergo surgery for this disease (171). Isolated palate
surgery composes majority of all these procedures. In general, the beneficial effect of
surgical treatment seems to vanish with time. The impact of surgery on cardiovascular
outcomes is not known. There is some evidence that surgery may decrease CRP levels
independent of bodyweight in adults with OSA (172).
Tracheostomy. Since the dawn of OSA surgery, tracheostomy has been the only definitely
curable operative treatment (173). This bypasses the UA and thus eliminates the obstructive
episodes during night. However, it is not widely used nowadays because of its invalidizing
nature.
Nasal surgery. Isolated nasal surgery (septoplasty, polypectomy, conchal operation) for
OSA has a low success rate, but it may have an impact on sleep quality, daytime sleepiness,
and it may help those individuals with CPAP (174,175). However, a patent nasal airway is
important for minimizing mouth breathing, because an open mouth worsens upper airway
obstruction  by  forcing  the  lower  jaw  to  rotate  downward  and  backward,  pushing  the
tongue into the posterior pharyngeal space (176).
Surgery of the soft tissues. Uvulopalatopharyngoplasty or an equivalent palatal procedure
has been introduced to stiffen the soft palate and thus open the retropalatal region (Figure
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5). However, the success rate of UPPP has been reported to be as low as 40-50%, especially
in those patients with UA narrowing elsewhere than only in the retropalatal area (177).
Thus, persistent upper airway narrowing in the nonresected portion is the probable cause
for treatment failure. Soft palate radiofrequency ablation (RFA) is well tolerated but not
curative for sleep apnea (166,178,179). When administered also into the tongue base, its
effectiveness  may be  improved.  The genioglossus  advancement,  tongue base  surgery and
hyoid suspension for hypopharyngeal obstruction have now lost their attractiveness due to
poor long-term results (180).
A.         B.               C.
Figure 5. Examples of pharyngeal surgery. A. Normal pharynx, B. uvulopalatopharyngoplasty
(UPPP) and C. uvulopalatoplasty.
Surgery of the jaws. Maxillomandibular advancement has been found to be the most
effective surgical option after tracheostomy for OSA, and sometimes it can be as effective as
CPAP for severe OSA in terms of AHI and ESS (181,182).
Bariatric surgery. If one considers all levels of obesity, then it seems that the numbers of
individuals with severe obesity (BMI >40 kg/m2) are increasing most rapidly (183). Since
the conventional lifestyle and weight reduction interventions have often proven to be
ineffective in long-term follow-up in this group, the number of patients undergoing
bariatric surgery is increasing rapidly. It has favorable effects not only on obesity related
metabolic and cardiovascular diseases and mortality but also on symptoms related to OSA
(184-186). In OSA patients who have undergone bariatric surgery, the disease was cured or
alleviated in 85% of cases. The basic concept of bariatric surgery is to decrease the amount
of energy ingested daily by performing an operation which either makes the stomach
smaller (restrictive surgery) or results in malabsorption by bypassing part of the absorptive
alimentary tract.  A combination of these two procedures, laparoscopic gastric bypass, is
the most common type performed in Finland nowadays (141).
Drug therapy
A variety of drug therapies has been tried to treat OSAS. Regimens which increase UA
muscle tone, ventilatory drive or cholinergic tone during sleep have been investigated in
small studies, as well as those which decrease airway resistance, UA surface tension or
proportion  of  REM  sleep.  There  is  no  convincing  evidence  that  any  drug  therapy  is
successful (187). For those patients who suffer persistent daytime sleepiness on CPAP
treatment and no co-existing remediable cause is identified, a safe wake-promoting agent,
modafinil, can be considered (188).
Whatever the treatment, a follow-up PSG or unattended cardiorespiratory recording is
routinely indicated to acertain the effect of the method, and whether some other therapy is
still needed.
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2.2.8 OSA and related conditions
OSA results  in  disturbances  of  two major  homeostatic  systems –  oxygenation and sleep –
and  thus  it  is  not  surprise  that  OSA  is  linked  to  many  common  diseases  and  these  have
significance  at  the  level  of  individual  and  from  a  public  health  perspective.  The  close
association of obesity and OSA complicates the differentiation of these effects, i.e. whether
the co-morbid condition is secondary to OSA or to some other risk factor(s). The
mechanisms that may lead to increased risk of cardiovascular, cerebrovascular and
metabolic disorders among OSA patients are presented in Figure 6.
Figure 6. Possible mechanisms leading to increased risk of cardiovascular diseases in obstructive
sleep apnea
Cardiovascular diseases
Cardiovascular diseases (CVD) are highly prevalent, associated with excessive morbidity
and mortality (40% of all deaths in Finland in 2009 and 34% in the USA in 2007), and
responsible for huge economic costs (189,190). The Finns are among the highest risk
population for coronary artery disease [CAD] in Europe (191).  In particular, severe OSA in
young  and  middle-aged  men  is  associated  with  a  risk  of  CVD  (CAD,  stroke  and  heart
failure) (192,193), and CPAP therapy had reduced cardiovascular events, even if it is only
the mild form of the disease, if the patients have other risk factors (4,194).
OSA presents autonomic, hemodynamic and respiratory challenges to the heart and
vascular system. These challenges are accentuated in a diseased myocardium. Especially
hypoxemia, arousals from sleep and intrathoracic pressure swings are responsible for
cardiovascular consequences (195). Moreover, many OSA patients have additional
traditional risk factors for CVD, e.g. obesity and high cholesterol levels.
Pathophysiological mechanisms (196,197). There are several pathophysiologial mechanisms
which mediate the harmful effects of hypoxemia: directly i.e. the decreased myocardial
oxygen  delivery  may  result  in  ischemia;  indirectly  i.e.  hypoxia  increases  expression  of
inflammatory mediators and genes which code for vasoconstrictive and platelet
aggregating substances, and suppress the production of vasodilatators and deaggregators.
Re-oxygenation leads to the production of free oxygen radicals (oxidative stress). These
mechanisms may evoke endothelial dysfunction, vascular inflammation and remodelling.
Hypoxia, arousals and changes in ventilation may increase sympathetic activity. During
normal NREM sleep sympathetic tone declines and parasympathetic tone rises, and vice
versa during REM sleep. During apneic episodes, hypoxia leads to a sudden reduction in
sympathetic tone, which then surges up in parallel with the rise in blood pressure and heart
rate. In sleep apnea, with recurrent apnea, overall sympathetic activity tends to increase.
The adverse effects of increased sympathetic activity include elevated ventricular load,
myocardial hypertrophy, tachycardia and arrhythmias.
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The increased intrathoracic pressure during apneas results in an increase in the
transmural pressure and left ventricular stress. Many of these mechanisms can be found to
persist during wakefulness: sympathetic activation, reduced heart rate variability, release of
vasoconstrictive agents and systemic inflammation. Vascular wall (endothelial) damage
and its dysfunction is responsible for this increased risk of atherosclerosis in OSA patients.
The endothelial damage is believed to be a result of hypoxemia/hyperoxia cycles, altered
autonomic control and oxygen free radicals. Loss of endothelial nitric oxide, increased
blood coagulability and fibrinogen levels and impaired vasodilatation also have an impact
on the CAD in OSA patients.
Hypertension. There  is  convincing  evidence  that  OSA  is  an  independent  risk  factor  for
hypertension (198-200). AHI and sleep time below 90% oxygen saturation are associated
with greater odds of hypertension in a dose-response fashion. Persons with mild OSA have
approximately two times the odds of suffering hypertension at four-eight years follow-up
compared  to  those  with  no  OSA.  It  seems  that  middle  aged  subjects  with  OSA  are  more
likely to develop hypertension than older individuals (201). From the opposite perspective
one can state that blunted decline in nocturnal blood pressure and drug-resistant
hypertension seem to be linked with OSA (197,202). Several studies suggest that both CPAP
(203-205) and OAs result in a reduction in blood pressure (206,207). The effect of CPAP on
hypertension is variable, those with severe OSA, resistant hypertension and good CPAP
compliance are most likely to benefit. On the other hand, anti-hypertensive agents are safe
in terms of OSA (187).
Coronary artery disease. The causal relationship between CAD and OSA is not so clear as it
is between hypertension and OSA. However, OSA may represent an additive or synergistic
risk factor for the development of CAD (192,208,209). Importantly, patients with OSA
without  overt  CVD  show  early  structural  and  functional  signs  of  atherosclerosis  (210).  In
cross-sectional  studies  in  the  general  population,  the  subjects  with  OSA  have  either  a
similar  or  only  slightly  increased  risk  for  overt  CAD  compared  to  subjects  without  OSA.
The  risk  seems  to  be  higher  in  clinical  based  samples.  In  community-based  follow-up
studies, there has been a modest increase in CAD risk in men (193). This risk is probably
higher in younger patients with more severe disease similar to the risk of hypertension.
OSA is overrepresented in CAD patients (192,211,212). Moreover, in those patients who
already have CAD and OSA, episodes of nocturnal ischemia are more common than in
those  with  no  overt  CAD  (213).  Furthermore,  ischemia  is  more  likely  to  occur  during
hypoxic, apneic and REM-sleep episodes. Effective treatment of OSA reduces the CAD risk
(4,209). Even a small reduction in blood pressure over the long term can decrease the
incidence of CVD and cerebrovascular disease (214), and CPAP use decreases blood
pressure, thus CPAP should have a protective effect against CVD also in hypertensive
patients.
Stroke. The risk for stroke seems larger than the risk for CAD events in OSA patients
(192). Moreover, OSA (even mild) is associated with about a 3-fold risk of cerebrovascular
events in those patients who have also CAD (215,216). In a recent paper, Redline and co-
workers described a community-based sample where men with moderate-to-severe OSA
had an almost a three-fold risk for stroke compared with control subjects (217).
Interestingly, untreated mild-to-moderate sleep apnea displayed an association with stroke:
an increase of one unit of AHI increased the risk of stroke by 6%. The effect of treatment of
OSAS with CPAP on cerebrovascular events is unclear at the moment (216).
Heart failure. OSA predicts the development of heart failure in men (193). In a cross-
sectional analysis of a large community study, the odds ratio for self-reported heart failure
was 2.38 in patients with sleep-disordered breathing vs controls (192). The prevalence of
sleep apnea is about 50% in patients with chronic heart failure, with the central type sleep
apnea being more common (218). At the moment the impact of OSA treatment is unclear
(but probably beneficial) (218).
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Rhythm disorders. OSA is characterised by brady-tachycardia cycles: during hypoxemia
caused by obstructive apnea, the vagal response leads to bradycardia; at the apnea
termination, a transient tachycardia occurs due to triggering of sympathetic system (196).
Recent observational studies have also shown increased nocturnal dysrhythmias (especially
atrial fibrillation) in patients with OSA in dose-dependent manner, but there is no solid
evidence for a beneficial effect of CPAP on these rhythm problems (153,154,197,219-221).
Metabolic syndrome and diabetes
Metabolic syndrome. The relative role of obesity and OSA in the pathogenesis of metabolic
alterations is unclear but there is a link (possibly obesity itself) between OSA and metabolic
abnormalities. The metabolic syndrome (MetS) is a cluster of risk factors for diabetes, CVD
and mortality in the general population (222). It includes disturbances in glucose
metabolism (insulin resistance), abdominal obesity (excess visceral fat), dyslipidemia
(hypertriglyceridemia and decreased high-density lipoprotein) and hypertension, the exact
definition depending on the authority issuing the guideline (223).  Metabolic syndrome is
common in OSA patients, the risk being about five-fold compared with controls, and more
than 2/3 of newly diagnosed MetS patients have OSA (224-226). In many studies, the degree
of OSA has been predictive of MetS prevalence (224,225,227-229). In fact, a recent report
suggested that OSA could be the second most important determinant after obesity for MetS
(230).
Diabetes. As  could  be  expected  on  the  basis  of  connection  between  OSA  and  MetS,  the
link between OSA and impaired glucose metabolism (glucose intolerance, insulin resistance
and type 2 diabetes mellitus [T2DM]) is quite convincing. Most epidemiological and clinical
cross-sectional studies have observed that OSA is associated with impaired glucose
metabolism, independent of body size, and this association becomes ever clearer with
increasing AHI and hypoxemia (225,231-236). However, prospective studies on OSA
patients have reported conflicting results on the development of diabetes, and thus the
causality is still unclear (234,237,238). In patients with T2DM, the prevalence of OSA is
high, > 75% (239,240). Moreover, increasing severity of OSA has been associated with
poorer glucose control thus supporting OSA treatment in these patients (240). The
association between sleep apnea and T2DM may be bidirectional: firstly, hypoxemia and
fragmented/deprived sleep have a negative effect on glucose metabolism (231,241,242).
Inflammatory cytokines released from adipocytes (e.g. interleukin [IL]-6 and tumor
necrosis factor [TNF]-), reactive oxygen speaces, increased sympathetic activity and
alterations in hypothalamic-pituitary-adrenal function (e.g. reflected in blood cortisol) may
be mechanisms mediating this relationship (225,231,241-243). Secondly, diabetes may
impair the reflex responses to hypoxia and hypercapnia which promote periodic breathing
and hypoxemia thus leading to deeper desaturations (244-246). The suspected beneficial
effect of CPAP treatment on metabolic problem is still not proven (247,248). It seems that
the patient profile (e.g. degree of obesity) and CPAP compliance may have an impact on the
outcome.
Other conditions
Even mild OSA has been linked with depressive symptoms (249,250).  The risk for traffic
accidents is also increased in OSA patients, and CPAP treatment seems to improve driving
performance (251,252).
Mortality
In the three epidemiological studies published so far, participants with moderate-to-severe
OSA have had a 1.5-3-6 fold greater risk of all-cause mortality compared to those without
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OSA (5,253,254). The risk for cardiovascular mortality is even more elevated. The risk is
largest in those subjects with severe OSA and men 40-70 years of age, and hypoxemia was
independently associated with mortality. In clinical samples, similar findings of elevated
CVD related and all-cause mortality have been demonstrated (4,255,256).
2.2.9 OSA and health economics
Sleep apnea incurs costs to the patient, to his/her employer and to society as a whole. Direct
costs include those related to the management of OSA and associated medical conditions.
OSAS patients are heavy consumers of health-care resources: the medical costs of patients
with (undiagnosed) OSA are twice those of matched controls, with women and the elderly
being the most expensive OSA subjects, and even mild sleep apnea is associated with
increased healthcare utilization (257-260).  Daytime sleepiness and sleep problems per se
are linked with increased health care utilization as well (261,262). The indirect costs are
mainly related to reduced working capability and increased risk of accidents. Sleep apnea
increases the risk of sickness absence and disability pension before and after OSA diagnosis
(263,264). As before, this risk is higher in women compared to men. The cost-effectiveness
of CPAP treatment has been demonstrated to be favorable (265,266).
2.3 INLAMMATION
2.3.1 Definition of inflammation and cytokines
Inflammation. Inflammation (Latin, inflammare, to set on fire) is the major local protective
process to tissue injury and is thus an integral part of immunity. The immune response is
aimed at eliminating injurious stimulus and the consequences of the injury (e.g. necrotic
cells caused by bacterial infection), and to start the healing process to guarantee the
survival of the individual. The immune response can thus protect an individual against
diseases.  The  response  is  generated  by  the  immune  system  which  consists  of  an  army  of
both rapid deployment troops for the first response (innate immunity) and well equipped
special  forces  with  their  sophisticated,  comprehensive  and  powerful  combat  abilities
(adaptive immunity) (267). Changes in circulating leukocytes (white blood cells), plasma
proteins and blood vessels are essential in inflammation. There is also a systemic reaction
known as the acute-phase response, characterized by changes in acute-phase proteins (the
best known of these proteins is C-reactive protein [CRP]), inflammatory cytokines,
biochemical parameters, body-temperature, nutrition and behaviour (268). (269,270)
Triggers for acute inflammation include microbes, tissue necrosis, hypoxia, foreign
bodies and immune reactions. Normally, in the acute response to a harmful stimulus, i.e.
acute inflammation, the immune responses wane with time due to antigen elimination,
short half-lives of mediating compounds, and appropriate control and negative feedback
mechanisms built into this system. On the other hand, if this does not happen and chronic
inflammation ensues, these inflammatory mechanisms are capable of damaging normal
cells  and  endothelium  and  actually  cause  diseases.  In  chronic  inflammation,  both  tissue
injury and attempts to repair the damage are being implemented. Moreover, chronic
inflammation may begin insidiously, as a low-grade response. Diseases with etiological
origins in immune-mediated inflammatory processes include autoimmune diseases (e.g.
rheumatoid arthritis) and allergic diseases (e.g. asthma). The non-immune mediated
inflammatory diseases include atherosclerosis, where toxic endogenous lipid components
may induce the process. In these kinds of systemic inflammation, the inflammatory process
is  not  confined to  a  particular  tissue but  involves  the  endothelium as  well  as  other  organ
systems. (269,270)
Cytokines. Cytokines are short-acting proteins which are produced after a triggering
event by many activated cell types (e.g. macrophages, endothelial cells, even adipocytes)
and act as hormone-like soluble mediators modulating the functions of other cells (270,271).
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They are essential in inflammation by recruiting leukocytes to the tissues where an
injurious agent is present (e.g. TNF-).  Moreover, cytokines participate in the regulation of
cell growth and activation, tissue repair and morphogenesis. The effect of a single cytokine
on different target cells can be diverse (272). The first cytokines were found to mediate
communication between leukocytes and thus were named interleukins. Other important
cytokine groups include interferons, TNF- and  cell  type  specific  growth  factors.  Even
though multiple cytokines may have similar functional effects and they can partly replace
and regulate each other, cytokines act in a highly regulated cascade:  for example, TNF-
stimulates IL-1, IL-1 regulates its own receptors and the IL-6 response, and IL-6 inhibits
TNF- (268). IL-6 is also the main activator of CRP production in the liver. Sometimes there
are failures in cytokine regulation and this inappropriate cytokine production triggers or
worsens a disease.
Although there is very complex networking of cytokines, they can be classified into pro-
inflammatory cytokines (e.g.  TNF-, IL-1, IL-6), which augment the inflammatory
response, and anti-inflammatory cytokines (e.g. IL-10 and IL-1 receptor antagonist [Ra]),
which attenuate inflammation. The exact function will depend on the specific cytokine but
in general, pro-inflammatory cytokines induce inflammation by endothelial activation, by
stimulating chemokine and cytokine secretion, by leukocyte stimulation, and they induce
acute phase reactions. They may also stimulate tissue repair through the fibroblasts. In the
pathogenesis of CVD, pro-inflammatory cytokines have an essential role because there is
dysfunctional endothelium. When present in large amounts, these cytokines have systemic
actions such as fever, cachexia, lost of blood pressure, disseminated intravascular
coagulation, hypoglycaemia, which can be extended into septic shock, and sleepiness.
(271,273,274)
The exclusively anti-inflammatory cytokines include IL-1Ra and IL-10. IL-1Ra is
structurally  similar  to  IL-1  and  binds  to  the  same  receptors,  but  it  is  biologically  inactive
and thus prevents IL-1 from transmitting a signal into the cell. In other words, it is a natural
antagonist or regulator of IL-1’s biological effects. It has an important role in the
suppression of the IL-1 induced atherogenesis in the vascular wall, and of -cell destruction
in the pancreas (275,276). IL-10 is the major inhibitor of inflammation e.g. by down-
regulating the production of pro-inflammatory cytokines and modulating or terminating
the inflammatory responses (277). (271,272)
Disease launching properties of cytokines can be targeted in the development of
treatment options for these diseases. TNF-inhibitors and anti-IL-6 agents have been used
for the treatment of autoimmune disorders such as rheumatoid arthritis. One of these
agents, etanercept, has decreased the degree of sleepiness in obese sleep apneics which is
not  surprising  in  view  of  the  sleep  promoting  property  of  IL-6  (278).  Anakinra,  a  human
recombinant form of IL-1Ra, has been evaluated in the treatment of rheumatoid arthritis, as
well. (271)
2.3.2 Assessment of inflammation
In (acute) inflammation, the physical signs of pain, redness, swelling, heat, dysfunction,
fever and tiredness represent the visible markers of disease. Estimation of changes in CRP
can be a useful way to evaluate the presence, intensity and type (bacterial vs. viral) of
inflammation and response to treatment (279,280). In terms of clinical inflammation, CRP
values less than 10 mg per liter are unimportant, and most normal subjects have values less
than 2 mg/L (268). On the other hand, CRP concentrations in this gray zone of 2-10 mg/L
have been linked with low-grade inflammation. For example, CRP concentration > 3.0 mg/l
is associated with an increased risk for CVD (281). High-sensitivity CRP (hsCRP) refers to
the  measurement  of  CRP  using  methods  with  sufficient  sensitivity  to  quantify  CRP
throughout its normal range. HsCRP concentrations (< 10 mg/L) are quite stable in the same
individual across 24 hours and are thus a good tool for estimating low-grade inflammation
(282).
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Cytokine measurements could be used as markers of inflammation as well. However,
they are seldom used in clinical practise due to their short half-lives, high costs, limited
availability and lack of standardization of the measurements (268).  On the other hand,
circulatory levels of cytokines represent the average value of all cellular sources, and thus
the blood concentration of a single cytokine does not necessarily provide relevant details
about the activity level of the whole cytokine cascade, or the intracellular activity (272,274).
Moreover, obesity and other co-morbidities, exercise, medications and hereditability can all
affect cytokine and CRP levels.
2.3.3 Inflammation in OSA, obesity, cardiovascular diseases and (pre)diabetes
Inflammation and OSA
Inflammatory compounds, and many other neurotransmitters, are integral part of sleep
regulation in normal physiological conditions and in diseases (283,284). For example, the
pro-inflammatory cytokines IL-1, TNF- and IL-6 have sleep promoting abilities: they
enhance sleep, if injected; if inhibited, the amount of sleep is reduced. The concentration of
these  cytokines  varies  in  the  brain  with  sleep  propensity;  they  act  on  sleep  regulatory
neuronal circuits and their levels are altered in conditions with enhanced sleepiness. On the
contrary, the two anti-inflammatory cytokines IL-10 and IL-1Ra are able to inhibit sleep.
Alterations  in  the  levels  of  inflammatory  compounds  have  been  reported  in  OSA  with
intermittent hypoxia being one potential mechanism mediating these changes.  Hypoxia
functions as a danger signal for the immune system by inducing the synthesis of
inflammatory cytokines and the expression of adhesion molecules in different cell types
and tissues (eg. vascular endothelium) due to oxidative stress (274). Accordingly,
hypoxemia of high altitude has been reported to induce an increase in circulating
concentrations of cytokines in healthy subjects (285). On the other hand, sleep deprivation
caused by repetitive microarousals in sleep apnea may explain part of the elevation in the
levels of pro-inflammatory cytokines (278,286,287).
However, it remains inconclusive whether the changes in circulating inflammatory
biomarker levels are due to OSA per se or to some other underlying factors such as excess
weight and co-morbidities. Thus, conflicting results have been found in all of the
biomarkers of inflammation which have been studied: 1) both reports of increased levels of
TNF-, IL-6 and CRP independent of body weight (288-293,293-306) and 2) papers
reporting that the increase in these biomarkers, if found, is mostly dependent on excess
weight (or the groups were not matched for body weight) have been published
(288,305,307-317). The IL-1()  levels  do  not  seem  to  be  elevated  in  patients  with  OSA,
although the plasma levels of IL-1 may increase after an apeneic event (288,295,296,315).
Many of the above studies have shown that pro- inflammatory biomarker levels correlate
with the severity of OSA. However, most of the studies have included a heterogeneous
group  of  patients  with  different  degrees  of  OSA,  and  very  few  studies  have  included  a
subgroup analysis especially with mild degree OSA patients. In these few studies, the levels
of pro-inflammatory biomarkers have not seemed to differ significantly from the levels
measured in control subjects (290,292,294,303,310,312) except for the CRP level in a Chinese
study (318).
There are very few studies on the levels of anti-inflammatory cytokines in adult sleep
apnea and in these reports, the subjects have suffered from moderate-to-severe OSA. The
intracellular levels of IL-10 in OSA patients depend on leukocyte type, some cells
displaying increased production, but all in all, it seems that a pro-inflammatory state
predominates (274). The circulating levels of IL-10 decrease as the sleep apnea worsens
(296). OSA patients with moderate-to-severe have also decreased IL-10 levels compared to
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controls. Treatment of sleep apnea does appear to elevate the IL-10 concentrations (319) but
changes in weight may have an impact on this improvement.
As could be expected, the effect of CPAP or surgery on inflammation in OSA patients is
also  unclear,  with  both  pro-  and  con-studies  having  been  published
(290,292,294,295,312,315,315,320). On the other hand, the effectiveness of CPAP treatment
on inflammation may increase with greater hours of use (321-324). However, the clinically
significant effects of CPAP on subclinical inflammation in OSA, particularly in overweight
patients,  still  need  to  be  established:  In  recent  randomized  controlled  studies,  CPAP  was
claimed not to have any effect on IL-6, TNF- or CRP levels in patients with moderate-to-
severe OSA (325,326). On the other hand, Drager et al reported a significant decline in CRP
concentrations in patients with severe OSA (156). Additionally, CPAP treatment did not
improve hypercytokinemia or insulin resistance in obese patients with OSA, and the
withdrawal of CPAP was not associated with an increase in the inflammatory markers
(312,327). Moreover, the poor compliance of mild OSA patients with CPAP provides more
support  for  choosing weight  loss  or  other  therapy in  this  group of  patients.  On the  other
hand, there are no studies where the effect of weight loss has been investigated on this issue
either.
Inflammation and obesity
Obesity is a condition where there is excessive adipose tissue (increased size or number of
adipocytes) which develops as a consequence of an imbalance between energy intake and
energy expenditure (328). The BMI is the most widely used measure of obesity (141). It is
calculated by dividing the individual’s weight in kilograms by the square of the
individual’s height in meters (kg/m2). Overweight is defined as BMI 25.0-29.9 kg/m2 and
obesity as BMI 30.0 kg/m2.  White  adipose  tissue  is  considered  not  only  to  be  an  energy
storage site but also an active endocrine organ releasing a large number of proteins
(adipokines) which regulate many systemic processes such as food intake, metabolism and
inflammation (329). In addition, adipose tissue secretes many inflammatory mediators
including cytokines (e.g. IL-6, TNF-, IL-10 and IL-1Ra) (330,331). In white adipose tissue, it
is the macrophages that are essential for the production of cytokines (332).
Thus, it is not surprising that obesity can be viewed as a low-grade inflammatory
condition. The primary cause of obesity associated inflammation is not clear, a role for
hypoxia and macrophage infiltration due to adipocyte death has been postulated (333,334).
However, it is clear that high BMI and weight gain, and especially a large amount of
visceral fat, have a connection with elevated circulating levels of the pro-inflammatory
biomarkers (335-337). Accordingly, cytokine production in visceral fat has been shown to
be greater than in subcutaneous fat (338,339). The increase in cytokine levels by weight gain
seems to be larger in those individuals who were more obese at baseline, this being
independent of other inflammatory diseases (337). This could have a connection with the
fact that obese subjects have carried a higher total adipocyte number than lean individuals
since childhood (340). Weight loss has a lowering effect on the levels of both pro-
inflammatory (341,342) and anti-inflammatory biomarkers  (343). Obesity is a risk factor not
only for OSA, but also for many diseases such as CVD, diabetes and cancer (344-346), and
inflammation may be one linking mechanism.
Inflammation in cardiovascular and cerebrovascular diseases
Atherosclerosis, which in the form of CVD and cerebrovascular diseases continues to be an
important  cause  of  morbidity  and  mortality  around  the  world,  is  a  dynamic  and
progressive disease of the inner layer of the arterial wall. A subclinical malfunction in this
inner layer, endothelial dysfunction (pro-atherogenic and pro-inflammatory state), is the
fundamental cornerstone of this disease (347,348). The normal endothelium regulates
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vascular tone (constriction vs. dilatation) and is the site of interaction between the vessel
wall, vasoactive compounds and cellular mediators in the blood. For example oxidative
stress, inflammatory mediators or hypercholesterolemia can launch this dysfunction, and
this will lead to a lack of nitric oxide. Atherosclerosis is characterized by the accumulation
of lipids, extracellular components, leukocytes, adhesion of platelets and proliferation of
smooth muscle cells in these lesions (349,350). Inflammation is considered as one of
important mechanisms in the pathogenesis and also in clinical manifestations of
atherosclerosis (e.g. acute myocardial infarction due to plaque rupture). In terms of OSA,
this inflammation is enhanced by the oxidative stress evoked by hypoxia/reoxygenation
cycles (274). Hypoxia functions as a danger signal for the immune system by inducing the
synthesis of inflammatory cytokines and promoting the expression of adhesion molecules
in different cell types and tissues (eg. vascular endothelium) due to oxidative stress.
Cytokines, which are mainly secreted by macrophages and T-cells in atherosclerotic lesions,
are one of the most important promoters and mediators in these processes.  For example,
IL-6 is expressed in atherosclerotic lesions and is predictive of future cardiovascular events
(351). Elevated levels of other pro-inflammatory molecules such as TNF-,  IL-1  and  CRP
can be detected in the peripheral circulation in affected individuals. Moreover,
atherosclerosis can be inhibited, or at least decelerated, by anti-inflammatory compounds,
for example IL-10 (352). An increased risk of CVD has been reported if the lifelong total
burden of infections is high (353). In the past years, there has been an on-going debate
about whether CRP can be used as a risk-marker for CAD. It seems that in patients with
intermediate risk, adding CRP into a risk prediction model may be beneficial (281).
Increased hsCRP (> 3.0 mg/l vs < 1 mg/l) is associated with CVD events but CRP is only a
marker of inflammation and not the direct cause of CVD (354).
Cytokine activation has also been connected with heart failure (355).
Inflammation in the metabolic syndrome and (pre)diabetes
It seems that the inflammatory condition, which is associated with excess weight as stated
above, is an essential finding in both the metabolic syndrome and T2DM (356,357). Insulin
resistance is a key element in both of these conditions: there is a failure of insulin to inhibit
glucose output from liver, and to promote glucose uptake in fat and muscle cells (358).
Moreover, in T2DM, there is a pancreatic islet -cell dysfunction, which is partly caused by
inflammation. In both of these conditions, there is an increase in the concentrations of many
pro-inflammatory biomarkers such as IL-1, CRP, IL-6 and TNF-. For example, TNF-  and
IL-6 mediate insulin resistance, and blockage of their signalling improve insulin sensitivity
at least in animal models (359,360). Thus anti-IL-1 therapies are promising new treatments
for T2DM (357). It is noteworthy that the level of the anti-inflammatory cytokine IL-1Ra is
increased in obesity, pre-diabetes and diabetes (343,361-363). It has been shown that
increasing components of the metabolic syndrome are associated with higher levels of
inflammatory biomarkers. Moreover, the levels of these biomarkers can predict the later
development of T2DM (364).
2.4 BACKGROUND TO THE PRESENT STUDY
The progression of OSA is very important in terms of public health: 1) in patient’s
perspective a more severe degree of OSA usually causes more symptoms, and it is a more
severe risk factor for co-morbidities. 2) Even now the number of snorers and OSA patients
who seek medical help is high. Thus, the focus has been on treating more symptomatic
patients and moderate-to-severe OSA. Based on the current knowledge researchers would
demonstrate that even early stages of OSA should be treated more actively than we do
nowadays. However, to succeed, we would need more infrastructure, medical staff and
money  to  do  that  work.  The  aim  of  the  present  study  was  to  investigate   the  natural
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evolution of  mild OSA and furthermore,  the  possible  chronic  inflammation related to  the
early stages of OSA.
Inflammation has proved to have an essential role in obesity and in the pathogenesis of
important co-morbidities of OSA. However, there are not so many papers on inflammation
in (mild) OSA. Thus, it seemed reasonable to clarify the connection between OSA and
inflammation and, on the other hand, to try to treat OSA in a way that would also alleviate
the inflammation. Weight loss, which is known to reduce inflammation and lower the risk
of OSA-related co-morbidities, thus seemed to be logical choice for implementing this kind
of therapeutic intervention.
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3 Aims of the Present Study
The aims of the present study were
1. To investigate the evolution of mild OSA after different treatment modalities.
(Study I).
2. To assess the evolution of symptoms related to mild OSA after surgical intervention
with a long term follow-up. (Study II).
3. To investigate the possible association between mild degree OSA and a range of
inflammatory biomarkers and also to evaluate whether this potential activation is
linked to the extent of respiratory events. (Study III).
4. To determine the impact of lifestyle changes aimed at weight reduction on
inflammatory biomarkers in overweight patients with mild OSA. (Study IV).
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4 Material and Methods
4.1 THE RETROSPECTIVE FOLLOW-UP
The retrospective part of the thesis was originally conducted to evaluate the evolution of
OSA and the outcome of different treatment modalities of mild OSA.
4.1.1 Patients and methods
In the follow-up studies I and II, medical records of adult patients who had visited the
Department of Otorhinolaryngology (ORL) at Kuopio University Hospital due to suspicion
of sleep disordered breathing between 1998 and 2004 were reviewed. Data on ORL-status,
sleep recording, treatment modality, sleep questionnaire, medical conditions and
medications were retrieved (Appendix 1). This sleep questionnaire (Appendix 2, questions
1-22) has been used in the Department of ORL since 1995 for all patients presenting with
suspicion of sleep disordered breathing. The same questionnaire, supplemented with an
inquiry into the patients’ opinions about the treatment they had received in the period since
their last visit (questions 23-28 in Appendix 2), was mailed to all those patients in 2005, for
whom  there  was  the  previously  mentioned  data  and  a  postal  address  was  available.  The
inclusion criteria for study I were age 18 years or older and mild OSA (AHI 5-15/h) verified
by full PSG or cardiorespiratory recording prior to any treatment. For the study II, an
additional criterion was that they had to have filled in the questionnaires at baseline and in
2005.
Study I retrospectively investigated the outcomes of different treatment options for mild
OSA in terms of AHI. The patients (in alphabetical order) who fulfilled the inclusion criteria
were  contacted  by  the  study  nurse  by  telephone.  The  first  50  patients  who  agreed  to
participate in the study visited the study nurse at the outpatient unit and underwent
overnight cardio-respiratory recording in 2005. Three groups were created: a) the untreated
group including those patients who underwent passive interventions such as lifestyle
counseling by an otorhinolaryngologist, a single consultation with a nutritionist or a
pulmonologist, instructions for positional therapy, or a short term unsuccessful CPAP
therapy due to poor compliance; b) the operative group i.e. those who had underwent any
upper airway surgical procedure due to sleep apnea; c) the CPAP group including patients
who were actively using CPAP treatment at the time of inquiry.
Study II investigated retrospectively the changes in the symptoms of the patients after
surgical treatment versus passive treatment for mild OSA. Those patients who were
regularly using CPAP were excluded from this study.
4.2 THE PROSPECTIVE TRIAL
The original randomized, clinical follow-up trial was conducted to determine the effects of
lifestyle  intervention  with  weight  reduction  in  patients  with  mild  OSA.   Studies  III-IV
which  examined  the  biomarkers  of  low-grade  inflammation  in  OSA  and  the  effects  of
lifestyle intervention on these markers were subanalyses of that larger trial.
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Figure 7. Studies III-IV flowchart
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4.2.1 Patients
The recruitment for the original prospective study started in October 2004, and ended in
December 2006. The participants were consecutively recruited from the adult patients
referred to the outpatient clinics of the Department of Otorhinolaryngology or Respiratory
Medicine of Kuopio University Hospital, in Kuopio, Finland because of suspicion of sleep
disordered breathing. Their weight, height and upper airways were checked, and
previously diagnosed diseases and prescribed medications were recorded. The patients
were eligible for participation if they were of working age (age 18-65 years), were
overweight or obese (BMI 26[28]-40 kg/m2), and had mild OSA (AHI 5-15/h). The exclusion
criteria were active treatment of OSA of any kind, chronic kidney or liver disease, untreated
thyroid disease or pregnancy. Moreover, all those patients whose blood samples were
inadequate for cytokine analyses, were excluded from analyses in studies III-IV. After the
visit  to  the  study  physicians  and  the  confirmation  that  the  patients  fulfilled  the  inclusion
criteria, the subjects were allocated in order of appearance randomly into two study groups
by a study nurse. A block randomization with a block size of 16 was used. At the
beginning, there was a plan to recruit one hundred patients for the study during the two
years but this goal was not reached. The study nurse did not take part in the intervention
part of the study, nor did the study nutritionist see the patients before the first group
session for the intervention group. No stratification was used in the allocation of the
participants into the two groups. The flowchart for studies III-IV is shown in Figure 7. Forty
patients who were not eligible for the study due to AHI less than 5/h served as a control
group for all OSA patients in the baseline measurements.
4.2.2 Methods
Procedures and measurements
In the prospective controlled trial (studies III-IV) all the patients with OSA had a baseline
visit and two follow-up visits with a physician, at three and 12 months.  The 40 non-apneic
patients, who served as control patients for the baseline measurements, were examined
once at baseline. At all these visits, the clinical assessments for all patients were done by an
otorhinolaryngologist and they included a complete ORL status, including examination of
pharynx and larynx in Müller’s manoeuvre with a fiber-endoscope. Moreover, special
attention was paid to possible obstructing sites in the upper airway (deviated nasal septum,
nasal polyps, large tonsils etc). The study nurse met the patients at the time points
mentioned  above  as  well  as  at  the  six  months  evaluation.  The  study  nurse  measured  the
height, weight, waist circumference between lower costal margin and iliac crest in the
standing position, hip circumference at the broadest level, greatest sagittal measure of the
stomach between ziphoid process and pubic symphysis, and horizontal measure of the
stomach from axillary to axillary line at the broadest level. Blood samples were taken after
overnight fast at 8.30-9.30 a.m. thirty minutes after insertion of an intravenous cannula and
bed  rest.  BMI  was  calculated  as  weight  (kg)  divided  by  height  squared  (m2). Body
composition, measured with an InBody 3.0 bioimpedance device (Biospace; Seoul, Korea),
and  blood  pressure  were  measured  by  a  trained  nurse  in  the  Department  of  Clinical
Physiology and Nuclear Medicine. The multifrequency bioimpedance method for
measurement of body composition provides detailed information on fat mass, total body
water and fat distribution within the whole body and segmental lengths. When compared
with the dual-energy X-ray absorptiometry method, Inbody analysis has provided a good
assessment of fat mass in healthy subjects (365). Blood pressure was measured from the
right arm with the subject in the sitting position, and was determined three times, after 10
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minutes of rest, using a standard sphygmomanometer. The mean value of the
measurements was used as the result.
The patients filled out several questionnaires of which only the Patient data –
questionnaire was utilized in the present studies III-IV (Appendix 3). The first eight
multiple choice questions were identical with those in the Snore Outcomes Survey (53).
Daytime sleepiness was assessed with the same questions than those in Epworth Sleepiness
Scale (49). The respondents were also asked whether their bedfellows had noticed breathing
pauses during their sleep and subsequently these were classified as "witnessed apneas."
Moreover, questions about daytime napping, sleep quality and daytime functioning were
asked. The questionnaires were filled out by the patients both at baseline and at the 1-year
visit.
The overnight in-home sleep study was performed in accordance with accepted
guidelines for diagnosis of OSA (66). Venla® cardiorespiratory recording device (Remote
Analysis, Kuopio, Finland) was used for six non-apneic patients at baseline, and Embletta®
(Embla, Broomfield, CO) for all the other patients. Both Venla® and Embletta® measured
oronasal flow and pressure by thermistor and pressure sensors, thoracoabdominal
respiratory effort  by bands,  snoring sounds by a  microphone,  SaO2 and heart rate from a
finger oxymeter, and body position by a sensor. The recordings were manually evaluated
by a blinded, trained physician. Apnea was defined as a cessation (more than 90%) of
airflow  for  more  than  10  seconds  with  oxygen  desaturation  of  more  than  4%.  Hypopnea
was defined as a reduction (more than 30%) of airflow for more than 10 seconds with
oxygen desaturation of more than 4%. The apnea–hypopnea index was defined as the
number of apneas and hypopneas per hour, and mild OSA was defined as an AHI of 5–15
events/hour. Other parameters were assessed, for example, arterial oxygen saturation, time
and percentage with arterial oxygen saturation below 90%, and heart rate. The sleep
recordings were conducted at baseline, at the 3-month visit, and at the 1-year visit. The
OSA was considered objectively cured when the AHI was less than 5 events per hour.
All the biochemical measurements were performed both at baseline and at the 1-year
visit in the Laboratory of Clinical Chemistry in Kuopio University Hospital. The blood
samples in EDTA tubes were centrifuged at 2100 g for 10 min. The tubes for serum samples
were allowed to clot for 30-120 min after which the serum was separated. Cholesterol, high-
density lipoprotein, triglycerides, alanine aminotransferase and glucose were determined
from fresh serum samples, using an automated analyzer system (Konelab 60 analyzer;
Thermo  Fisher  Scientific,  Waltham,  MA),  and  insulin  was  measured  with  a
fluoroimmunoassay technique (Wallac; PerkinElmer, Waltham, MA). Insulin resistance
measured by the homeostasis model assessment (HOMA-IR) was calculated as follows:
HOMA-IR=fasting glucose (mmol/l) × fasting insulin (mU/l)/22.5 (366). Extra tubes of EDT-
plasma and serum were stored at -70C, and inflammatory biomarkers from baseline and 1-
year samples were analyzed in single runs using these tubes.  Plasma levels of TNF-, IL-1,
IL-6,  IL-10  and  IL-1Ra  were  analyzed  with  high  sensitivity  ELISA  kits  (R&D  Systems,
Minneapolis, MN, USA). Serum hsCRP was analyzed by Immage® (Beckman Coulter Inc,
Fullerton, CA, USA) and a high sensitivity kit.
Intervention
At the beginning of the trial, the patients were informed about the general health risks
associated with OSA and obesity (including information about harmful lifestyle factors,
such as smoking and alcohol drinking). Both the doctor and the nurse stressed the
importance of diet and exercise to the control group. No specific individualized programs
were offered to the subjects in the control group.
The intensive lifestyle intervention lasted for one year, and consisted of 14 visits with the
study nutritionist. At the beginning, patients in the intervention group were asked to keep
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a 3-day food diary at baseline to estimate their nutrient intake. After screening, the
intervention group participants started with a group-based very low calorie diet (VLCD) of
600–800 kcal/day (Nutrilett® [Nycomed Pharma, Oslo, Norway], Modifast® [Novartis,
Basel, Switzerland], Nutrifast® [Leiras, Helsinki, Finland], or Naturdiet® [Vitamex,
Norrköping,  Sweden])  for  12  weeks.  At  the  beginning  of  the  intervention,  previous
attempts  to  lose  weight  were  discussed  and  an  individual  goal  was  set  for  weight  loss.
During the VLCD period, follow-up visits were arranged every second week and the
sessions were supervised by the nutritionist. Compliance with the program and
supervision for any possible adverse events were monitored by individual interviews at
each visit by the nutritionist. The weight was measured at every visit and the patients were
asked about any lifestyle changes he or she had made. The nutritionist provided face-to-
face counseling individually tailored to each patient in the intervention group and also took
part in the group sessions. Each session lasted 60–90 minutes. In addition to VLCD
products, the patients were allowed to have calorie-free drinks and vegetables in
accordance with our outpatient clinic's weight reduction program. The clinical nutritionist
provided dietary and lifestyle counseling at each visit, with the emphasis placed on diet,
exercise, and modification of lifestyle in general, specifically focusing on eating behavior.
After the VLCD program, the patients were advised to reduce fat to no more than 30% of
total energy by increasing their intake of fruits, vegetables, poultry, fish, and lean meat, and
by limiting dairy fats, fatty meat, sweets, pastries, and desserts. The subjects were
recommended to increase their overall level of daily physical activity, and endurance
exercise (such as walking, skiing, jogging, or swimming) was also recommended. After the
VLCD, a physiotherapist supervised two of the group meetings, which focused on circuit-
type resistance  exercise  to  improve functional  capacity.  None of  the  study subjects  in  the
intervention group had ongoing weight loss procedures, were enrolled into formal exercise
programs, or were provided with personal trainers. During the intervention period, the rate
of participation in these sessions varied from 70 to 80%.
Any possible adverse events related to the weight reduction program were assessed by
the nutritionist at the visits which took place every second week. All study participants
were also given the telephone number of the study nurse, if any questions or concerns
about their health should emerge. All the results of the laboratory tests, blood pressure
measurements, and electrocardiograms were checked by study physicians. It was decided
that  if  any  abnormal  test  results  endangering  the  health  of  the  study  participants  were
observed, then participants would be informed and referred for appropriate medical care.
4.3 STATISTICAL METHODS
In studies I-II, differences between groups were assessed with one-way analysis of variance
for continuous variables and Fischer’s exact test or Kruskal-Wallis test for categorical or not
normally distributed variables. Then the post hoc test for Kruskal-Wallis and Bonferroni
post hoc tests were used to compare individual characteristics between treatment groups.
In the study II, logistic regression models were used to compare the frequency of the
symptoms by adjusting for age, sex, BMI, AHI, baseline status of respective symptom and
the follow-up time.
Study  IV  was  an  explorative  substudy  of  an  existing  randomized  controlled  trial.  No
separate sample size calculation was done for study IV. The results can be considered as
explorative post hoc analyses regarding the effect of weight loss on inflammatory
mediators  in mild OSA patients with obesity.
Studies III-IV assessed differences between the groups by Fisher’s exact test and logistic
regression analysis with adjustment for age and sex for dichotomous variables, and t-test
and analysis of covariance with the same adjustments for continuous variables. Due to the
right-skewed distribution of the inflammatory markers, a logarithmic transformation was
applied before analysis. Geometric means and standard deviations (SD) are reported for
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these variables, i.e. the logarithmic values were converted back to the original scale via the
antilog. Age, sex, total body fat percentage and baseline level of the respective variable
were considered as confounding factors when analyzing the inflammatory markers. At
baseline, co-morbidities (hypertension, CAD, hypercholesterolemia, diabetes, asthma and
inflammatory diseases) and non-steroidal anti-inflammatory drug medication were also
taken into account as confounding factors. Additionally, there was further adjustment for
cardiovascular medication but because this analysis provided essentially the same result,
these are not separately shown in the figures. The inflammatory marker analyses were
performed at 12 months also by adjusting for lean body mass, waist circumference or BMI
instead of fat percentage, and the results were similar. Thus, it was decided to use fat
percentage because the accuracy of BMI as a descriptor of obesity is limited (56,57). Linear
and multiple regression analyses were used to identify independent determinants for
inflammatory markers.
In studies I-IV, 95% confidence intervals (CI) were calculated for the main results, and all
the analyses were performed on an intent-to-treat basis. Differences were regarded as
statistically significant if a two-sided P-value was less than 0.05. Data are expressed as the
number of cases or mean with the SD. Patient characteristics and variables were analyzed
with the Statistical Package for Social Sciences (software version 11.0.4-17.0 for Windows or
Mac, SPSS Inc., Chicago, USA).
4.4 ETHICAL ASPECTS
The studies were approved by the Research Ethics Committee of the Hospital District of
Northern Savo, Kuopio, Finland (17.8.2004, decision number 127/04) and they were
conducted in accordance with the Declaration of Helsinki (367). The patients were given
oral and written information about the trial protocol and they provided written consent.
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5 Results
5.1 RETROSPECTIVE STUDIES (STUDIES I-II)
The medical records of 592 patients were reviewed in the studies I-II. After excluding
those  patients  with  insufficient  data,  final  diagnosis  other  than  OSA,  death  during  the
follow-up, age <18 at the time of diagnosis and treatment, or unavailable contact
information, 362 potential study subjects were traced. Forty-one percent of them (147
patients) had mild degree OSA.
Of these patients with mild degree OSA at baseline, 50 were invited to undergo an
objective  assessment  for  OSA by control  polysomnography (study I).  Eleven of  them had
been provided with CPAP prior to this study, 11 had underwent surgical UA operation due
to OSA and 28 of them were considered as being untreated during the follow-up (Table 2).
The UA surgeries consisted of two tonsillectomies, five UPPPs, two RFAs of the soft palate,
one septoplasty and one nasal polypectomy. In patients with CPAP therapy, compliance
with the CPAP was good, average use per night being 6.4 hours. The subjects in all groups
were mainly male, middle aged, overweight/obese patients with mild OSA (see Table III in
the original publication I). The patients in the CPAP group were significantly older than in
the other two groups. At baseline, there was a significant difference (P=0.035) between
groups in the presence of obstruction in the pharynx due to anatomical structures: 96.4% of
untreated patients, 90.9% of patients in the operative group and 63.6% of patients in the
CPAP group had obstructive features as verified by an otorhinolaryngologist. Otherwise,
there were no statistically significant differences with respect to nasal obstruction, age,
bodyweight, BMI, BMI change during follow-up, follow-up time, male/female proportion,
smoking or AHI at baseline.
Table 2. Treatment modalities of study patients (n=50) in the study I.
Treatment group, n (%)
Treatment modality Untreated, n=28 Operative, n=11 CPAP, n=11
No treatment 1 (3.6)
A single session of
lifestyle counseling
19 (67.9) 5 (45.5) 4 (36.4)
Dietitian consultation 3 (10.7)
Pulmonologist
consultation
4 (14.3)
Instructions for
positional treatment
7 (25.0)
Dentist consultation 2 (18.1)
Surgery 11 (100)
CPAP 11 (100)
Terminated CPAP use 6 (21.4) 2 (18.1)
CPAP=continuous positive airway pressure.
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A letter with a follow-up questionnaire was mailed to all 362 individuals, of whom 287
(79 %) responded. However, patients with AHI>15/h, insufficiently filled questionnaires
and those with CPAP treatment were excluded from the study II. Thus, 81 patients (40 in
the operative group and 41 in the control group) with mild OSA were included in the
analysis  of  subjective  symptoms.  In  the  operative  group,  nine  RFAs,  four  tonsillectomies,
four uvulectomie, 23 UPPPs and septoplasties were done. The patients in the operative
group were younger at baseline (Table 3).  Weight, BMI, and BMI change, follow-up time,
male/female  proportion,  smoking  habits,  alcohol  consumption,  prevalence  of  CVD  and
metabolic diseases were similar in both groups. The mean follow up period was 2.9 (range
0.5-5.7) years.
Table 3. Characteristics of patients at baseline, study II.
Group, mean (SD)
Factors Control, n=41 Operative, n=40 P
Gender, men/women 38/3 35/5 0.482
Age, years 52.2 (8.9) 46.0 (8.4) 0.002
Weight (kg) 90.1 (14.5) 85.4 (12.9) 0.129
BMI (kg/m2) 29.1 (4.7) 27.6 (3.7) 0.119
AHI (events/hour) 9.3 (1.2) 9.2 (3.3) 0.855
Follow-up time 2.9 (1.2) 2.8 (1.4) 0.728
BMI=body mass index, AHI=apnea-hypopnea index. p value: Fisher’s exact test or T-test for equivalence
between groups.
5.1.1 Evolution of AHI in patients with mild OSA
The patients who were not actively treated experienced a statistically significant
exacerbation of AHI during the mean follow-up time of 4.1 years (range 1.3-9.0; SD 1.9)
(Figure 8). This was also statistically significant compared to the operative group, which
did  not  experience  a  change  in  their  AHI.  It  is  also  noteworthy  that  patients  with  CPAP
treatment did exhibit an increase in AHI. Sixty-four percent of patients in the CPAP group
developed at least moderate sleep apnea as measured by cardio-respiratory recording after
a one night wash-out period from the use of CPAP. The value for the untreated group was
50%, and for operated patients 18%.
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Figure 8. Mean apnea-hypopnea index (AHI) in untreated, operative and continuous positive airway
ressure (CPAP) treatment groups at baseline and at control measurements. Reprinted with permission by
John Wiley and Sons. Sahlman J et al., Laryngoscope 117(6):1107-11, 2007.
5.1.2 Evolution of the symptoms related to sleep apnea
At baseline, patients in the operative group were less alert in the morning (P=0.003) than
those in the control (passive treatment) group. Otherwise, there were no significant
differences in any of daytime or night-time symptoms between the two groups (Tables 4
and 5).
However, untreated patients had a worse progression of their sleep apnea symptoms
compared to operated patients: there was no improvement in any of their daytime
symptoms, and there was an increase in all night-time symptoms, except for snoring
intensity. With respect to the daytime symptoms, daytime sleepiness and tiredness at work
were significantly less prevalent among the operated patients than in the control patients.
Odds ratio for daytime sleepiness and tiredness at work were 0.05 (95% CI 0.01-0.25,
P<0.001) and 0.19 (95% CI 0.05-0.70, P=0.005), respectively, in the operated group compared
with the untreated patients.
In terms of night-time symptoms, the operated group displayed less snoring, fewer
apneas and less insomnia, and their sleep quality was better at follow-up. Adjusted odds
ratio for frequent snoring was 0.15 (95% CI 0.03-0.75), for intensive snoring 0.06 (95% CI
0.02-0.22) and for better sleep quality 0.15 (95% CI 0.03-0.69) in the operated group as
compared with the control group.
There was no difference between the surgical procedures in terms of reducing the
proportion of symptomatic patients in either daytime or night-time items.
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Table 4. Daytime symptoms of the study patients at baseline and follow-up (study II)
Group, %
Parameter Control, n=41 Operative, n=40 P
Daytime sleepiness
Baseline 87.2 95.0
Follow-up 89.7 65.0 <0.001
Tired at work
Baseline 55.0 61.5
Follow-up 55.0 32.5 0.005
Not alert in the morning
Baseline 38.2 76.5
Follow-up 41.9 36.8 0.128
Falling asleep easily while watching TV
Baseline 72.5 60.0
Follow-up 80.5 52.5 0.128
P: likelihood-ratio test, adjusted for age, sex, body mass index, apnoea-hypopnea inex, baseline
symptom status and follow-up time.
5.2 PROSPECTIVE STUDIES (STUDIES III-IV)
Study III involved 84 patients with mild OSA, and 40 controls recruited from those subjects
who had AHI <5/h. Of these mild OSA patients,  three were excluded from study IV since
their BMI was less than 28 kg/m2. Moreover, nine subjects dropped out later during the one
year follow-up. The reason for dropouts were a dislike of the VLCD products in two cases,
work-related schedule problems in six cases, and a death not related to OSA in one case.
Moreover, 12 subjects had a missing cytokine analysis at 12 months due to an insufficient
blood sample. One patient was excluded due to high hsCRP (>10) at baseline. Thus, study
IV included those 59 sleep apnea patients (28 in the intervention group and 31 in the control
group), who had both baseline and 12 mo cytokines measurements available and had
participated in the prospective controlled trial for the 12 months (Flow chart in Figure 7).
In study III, patients in the non-apneic control group were younger (mean 45.6 years, SD
11.5) than patients with mild OSA (mean 50.4 years, SD 9.3), P=0.013 (see Table 1 in the
original publication III). In study IV, OSA patients in the intervention group were heavier,
Table 6. The analyzed sleep recording time was longer in the control group (434 min vs. 382
min,  P=0.028).  However,  the  time  of  over  six  hours  also  in  the  intervention  group  can  be
considered as more than adequate for a reliable analysis. Otherwise the groups were similar
in terms of the other sleep apnea indices, chronic diseases and medications.
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Table 5. Night-time symptoms of the study patients at baseline and follow-up (study II)
Group, %
Parameter Control, n=41 Operative, n=40 P
Frequent snoring
Baseline 80.0 94.9
Follow-up 86.8 71.4 0.014
Intensive snoring
Baseline 89.5 97.3
Follow-up 75.0 35.0 <0.001
Witnessed apneas
Baseline 35.3 50.0
Follow-up 76.5 13.8 <0.001
Poor quality of sleep
Baseline 41.9 54.8
Follow-up 60.6 36.1 0.033
Frequent awakenings
Baseline 58.5 60.0
Follow-up 65.9 50.0 0.133
Insomnia
Baseline 35.0 35.0
Follow-up 41.5 22.5 0.022
Nocturia
Baseline 36.8 36.1
Follow-up 52.6 34.3 0.747
P: likelihood-ratio test, adjusted for age, sex, body mass index, apnoea-hypopnea inex, baseline symptom
status and follow-up time.
During the 1-year of follow-up the mean change in weight was -10.7 kg (10.4 % of the
initial weight) in the intervention group, and -2.9 kg (3.2 %) in the control group (P<0.001).
A marked difference was found in all anthropometric measurements (BMI, fat % and waist
circumference)  between  the  two  study  groups,  although  some  significant  improvements
took  place  also  in  the  control  group.  The  intervention  group  achieved  more  marked
metabolic improvements, and the insulin level improved more in the intervention group
compared with the control group (P=0.021). There were no statistically significant
differences in the prevalence of smoking or chronic diseases between groups at 1-year.
(Table 7).
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Table 6. Patient characteristics at baseline, study IV. The data present proportions given as
percentages (%) or mean values with standard deviations (SD).
Group, (SD)
Control, N=31 Intervention, N=28 P
Men, % 71 82 0.270†
Age, years 51.8 (9.0) 52.5 (8.8) 0.576‡
Weight, kg 91.4 (10.5) 102.0 (12.9) 0.001
BMI, kg/m2 31.5 (2.5) 33.5 (3.0) 0.007
Total body fat, % 29.0 (7.0) 30.1 (6.9) 0.035
Waist circumference, cm 105 (6.3) 113 (9.2) 0.035
Plasma fasting glucose, mmol/l 6.1 (1.7) 6.5 (2.7) 0.632
Serum insulin, mU/l 10.8 (4.6) 13.9 (7.3) 0.085
HOMA-IR 2.9 (1.7) 4.3 (3.9) 0.114
Plasma total cholesterol, mmol/l 4.7 (1.0) 4.6 (0.7) 0.491
Plasma HDL cholesterol, mmol/l 1.1 (0.3) 1.0 (0.2) 0.296
Plasma triglyserides, mmol/l 1.8 (1.0) 1.7 (1.2) 0.829
Plasma ALT, U/l 34 (25) 39 (20) 0.571
Systolic blood pressure, mmHg 129 (13.7) 133 (10.6) 0.158
Diastolic blood pressure, mmHg 80 (8.5) 81 (8.2) 0.713
Current smoker, % 25.9 7.4 0.074
Hypertension*, % 35.5 53.6 0.163
Coronary artery disease*, % 3.2 3.6 0.864
Diabetes*, % 9.7 14.3 0.579
AHI, events/h 9.6 (3.0) 10.0 (3.0) 0.502
Mean SaO2, % 94 (1.2) 94 (1.5) 0.349
SaO2 below 90%, % 1.4 (3.3) 3.0 (5.5) 0.162
ESS 10.0 (5.1) 10.2 (4.9) 0.824
Mean heart rate, beat/min 58 (7.5) 59 (7.8) 0.379
P: P value from logistic regression analysis for dichotomous variables, ANCOVA for continuous variables;
adjustment for age and sex. BMI=body mass index, HOMA-IR=the homeostasis model assessment of
insulin resistance,  HDL= high-density lipoprotein, ALT=alanine aminotransferase, AHI=apnea hypopnea
index, SaO2= oxygen saturation. †Adjusted for age. ‡Adjusted for sex. * self reported
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Table 7. Changes in anthropometric, biochemical and cardio-respiratory recording parameters
after the 1-year intervention. The data present mean changes with standard deviation (SD).
Study IV.
Group, change (SD)
Control, N=31 Intervention, N=28 P
Weight, kg -2.9 (6.5)** -10.7 (6.1)*** <0.001a
BMI, kg/m2 -1.01 (2.2)** -3.53 (2.0)*** <0.001a
Total body fat, % -0.75 (3.2) -5.11 (3.5)*** <0.001a
Waist circumference, cm -3.70 (6.6)** -11.6 (6.4)*** 0.001a
Plasma fasting glucose, mmol/l -0.44 (1.5) -0.75 (2.5) 0.827
Serum insulin, mU/l -1.00 (3.6) -6.54 (7.4)*** 0.021
HOMA-IR -0.43 (1.3)* -2.45 (4.0)** 0.057
Plasma total cholesterol, mmol/l 0.01 (0.7) -0.18 (0.8) 0.693
Plasma HDL cholesterol, mmol/l 0.09 (0.2)** 0.12 (0.2)** 0.588
Plasma triglyserides, mmol/l -0.21 (0.7) -0.57(1.2)* 0.053
Plasma ALT, U/l -9.58 (21.1)* -15.6 (18.9)*** 0.150
Systolic blood pressure, mmHg -0.66 (7.9) 0.74 (10.7) 0.279
Diastolic blood pressure, mmHg 0.14 (6.2) -0.26 (6.7) 0.874
AHI, events/h -0.7 (7.6) -3.7 (6.0)** 0.297
Mean SaO2, % -0.05 (1.4) 0.87 (1.3)** 0.062
SaO2 below 90%, % 0.62 (3.9) -1.77 (4.3) 0.316
ESS -2.2 (3.0)*** -3.3 (4.0)*** 0.187
Mean heart rate, beat/min 0.87 (5.3) -3.06 (5.9) 0.090
P= p value from ANCOVA adjusted for age, sex, body mass index and baseline level of respective variable
for difference between groups. Asterisks indicate whether the change between follow-up and baseline was
significant in the respective group: *P<0.05, **P<0.01 and ***P<0.001; paired samples T-test.
BMI=body mass index, HOMA-IR=the homeostasis model assessment of insulin resistance, HDL=high–
density lipoprotein, ALT=alanine aminotransferase, AHI=apnea-hypopnea index, SaO2=arterial oxygen
saturation, ESS= Epworth sleepiness scale aNot adjusted for body mass index.
Total AHI decreased (-3.7/h, SD 6.0, P=0.003) and mean SaO2 increased (0.87, SD 1.3,
P=0.003) in the intervention group during the follow-up, but the differences between the
groups were not statistically significant (Table 7). Also the other sleep parameters displayed
a trend towards improvement in favor of the intervention group. Daytime sleepiness
decreased significantly in both groups, the difference between the groups being non-
significant.
Table 8 presents the inflammatory biomarker concentrations in the mild OSA group and
the  non-OSA  control  group  at  baseline.  The  level  of  TNF- was  higher  and  IL-1 lower
among OSA compared with control patients. The two anti-inflammatory cytokines, IL-10
and  IL-1Ra  were  higher  in  patients  with  mild  OSA  than  in  controls.  There  were  no
differences in the baseline concentrations of inflammatory markers between those patients
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who continued in the supervised lifestyle intervention group and those in the single session
lifestyle counseling group, i.e. the control group
Table 8. Baseline inflammatory biomarker concentrations in patients with and without mild
obstructive sleep apnea (OSA), Study III
Group
Mild OSA, N=84 Non-OSA, N=40 P
TNF- 1.54 (1.75) 1.17 (1.58) 0.004
IL-1 0.19 (1.51) 0.23 (1.31) 0.004
IL-6 2.36 (1.90) 2.14 (2.01) 0.893
hsCRP 1.67 (2.53) 1.30 (2.53) 0.087
IL-10 1.28 (2.34) 0.70 (1.51) <0.001
IL-1Ra 478 (1.65) 330 (1.97) 0.003
P: ANCOVA on logarithmically transformed variables adjusted for age, sex, body mass index, fat%, chronic
diseases and non-steroidal anti-inflammatory medication.
The  biomarker  levels  in  whole  study  III  population  were  examined  in  relation  to  OSA
severity (AHI and night-time oxygen saturation) at baseline. The hsCRP levels were higher
in patients with AHI 5-10/h and AHI>10/h compared with subjects with AHI <2/h (P=0.049
and P=0.009, respectively). IL-1 showed a decline in conjunction with AHI (P<0.001). The
concentration of IL-6 was found to be higher in patients who spent more time at SaO2 <90 %
during their sleep. The levels of both anti-inflammatory cytokines, IL-10 and IL-1Ra
increased with the amount of sleeping time spent at SaO2 <90 % (P=0.016 and P<0.001,
respectively)(See Tables 3 and 4 in the original publication III).
5.2.1 Changes in pro-inflammatory biomarkers
During  the  1-year  follow-up,  levels  of  IL-6  and  hsCRP  decreased  significantly  in  both
groups (Table 9). The decreases tended to be greater in the intervention group, but the
differences between the groups did not reach statistical significance. The change in AHI
was a significant determinant of change in hsCRP levels: =0.080, 95% CI 0.019, 0.141,
P=0.011. Insulin seemed to be related to IL-6 levels, (=0.082, 95% CI 0.001, 0.163, P=0.049 for
IL-6), but in multivariate analysis, the association vanished and only smoking remained as
a significant predictor of IL-6 level (=1.256, 95% CI 0.131, 2.382, P=0.029). Moreover, the
improvement in total body composition variables (mainly BMI) exhibited several
borderline significant (P=0.06) associations with hsCRP and IL-6. An hsCRP concentration >
3.0 mg/l, which is known to associate with increased risk for cardiovascular risk, was found
only in three patients out of those 14 patients who had hsCRP > 3.0 mg/l at baseline (seven
patients in both groups had a high value at baseline, and two patients in control group and
one patient in the intervention group had an elevated level at 1-year). No significant
differences were found either for TNF- or IL-1 levels between the groups. However,
improving nocturnal SaO2 was associated with decreasing TNF-:  change  of  SaO2 and
change of SaO2 <90% in the same model: =-0.536, 95% CI -0.834, -0.239, P=0.001 for SaO2,
and =-0.139, 95% CI -0.237, -0.041, P=0.007 for  SaO2 <90%.
5.2.2 Changes in anti-inflammatory biomarkers
There was a statistically significant reduction in the levels of IL-1Ra in the intervention
group compared with the control group (Table 9). The decrease in IL-1Ra was best
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explained  by  improving  insulin  metabolism  (=11,748, 95% CI 1.260, 22.237, P=0.029).
Weight loss was associated with a change in IL-Ra in the linear regression but in the
multiple regression analysis, this finding disappeared. A significant reduction of IL-10
occurred in the control group over the follow-up period. This was probably due to the
higher baseline levels, the reason for which remains unknown. The changes in IL-10 levels
were associated with improvements in body composition.
In the whole study population, no associations were found between the levels of
immune mediators and excessive daytime sleepiness measured by ESS.
Table 9. The 12 month changes in inflammatory biomarker concentrations in patients with mild OSA by
treatment group. Study IV
Group
Control, n=31 Intervention, n=28 P
TNF- 0.25 (1.14) -0.32 (1.44) 0.145
IL-1 0.10 (0.27) 0.18 (0.70) 0.788
IL-6 -0.73 (2.00)* - 1.51 (1.55)*** 0.079
hsCRP -0.68 (1.67)** -1.17 (1.67)*** 0.067
IL-10 -0.45 (0.83)** -0.25 (1.03) 0.962
IL-1Ra -38.6 (238) -147 (207)** 0.001
Padj: ANCOVA on logarithmically transformed variables adjusted for age, sex, fat% and baseline level of
respective variable. Asterisks indicate whether the change during the 12 months was significant in the
respective group: *P<0.05, **P<0.01 and ***P<0.001, paired samples T-test.
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6 Discussion
The  present  study  shows  that  untreated  patients  with  mild  OSA  experience  significant
symptoms related to this disease. Furthermore, the study supports the belief that OSA is a
progressive disease. In carefully selected patients, upper airway surgery can prevent the
exacerbation of both symptoms and AHI. Obesity is a major risk factor for OSA, and weight
loss is recommended in all clinical guidelines. However, until recently, there have been no
well-conducted studies on the effect of weight loss in the treatment of OSA (143-147). This
study demonstrated that there is an activation of the inflammatory system in overweight
patients with mild OSA. Furthermore lifestyle intervention with weight reduction was
observed to improve the signs of low-grade inflammation. These findings suggest that
active treatment should be provided already in the early stages of OSA to prevent the
progression of the disease and to reduce the risk for co-morbidities.
6.1 EVOLUTION OF MILD OSA
In studies I-II, the untreated patients experienced an increase of AHI and OSA related
symptoms independent of changes in weight.  The results of these present studies on AHI
are well in line with the earlier proposal that OSA is preceded by simple snoring, followed
by rapid increase in respiratory events and a plateau phase (368), as well as with the studies
in which a progression of snoring or OSA have been reported (2,73,75-81). However, there
are also reports which state that AHI does not deteorirate over time in untreated patients
(82-86). If one considers these studies, then three included an elderly population, and thus
support the proposal that the deterioration happens before old age (82,84,85). It is
noteworthy that the trials reporting no change in AHI included relatively small number of
patients (17-58 patients) while there were five large studies (160-2968 patients) among those
which all concluded that OSA does deteriorate with time. Our study did not include simple
snorers and thus we can not conclude if OSA is a continuum of snoring. If this would be the
situation, the treatment of simple snoring would become important.  Taken together, it
seems that age, time, body weight change and mild-to-moderate OSA at baseline are the
most important determinants of changes in OSA severity (2,73,80,81,83,85). Moreover, it has
been demonstrated that untreated patients have more severe oxygen desaturations and an
increased intensity of snoring. The evolution of OSA symptoms has not been studied
extensively previously: there do not seem to be significant changes in daytime sleepiness as
measured my ESS (2,86)  and multiple sleep latency test (83) in untreated patients even
though the ESS scores were usually higher at the follow-up.
In the present study, operative treatment was found to represent a good and effective
alternative for the treatment of mild OSA, when used selectively. However, this study did
not elucidate criteria for operative treatment. The role of operative treatment in OSA is
controversial due to the paucity of randomised controlled studies and the lack of long-term
outcome reports. However, surgery has been recommended for mild-to-moderate OSA in
non-obese patients (369). As reviewed earlier, the best result of surgical treatment on OSA
has been achieved with operations targeted to treat retropalatal obstruction compared to
retrolingual obstruction with or without retropalatal obstruction (177). This is in accordance
with the present findings that case-to-case selection of nasal or retropalatal obstruction is
beneficial in the long run.
The finding of non-significant worsening of AHI in patients on CPAP treatment is in line
with earlier reports that CPAP improves but does not cure OSA. However, it has to be used
every night because the benefit is not sustained, though the AHI level may remain
decreased after one night without CPAP (370,371). Due to the short washout period in the
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present study, the results on AHI for the CPAP group could have been even worse if
measured after a longer washout period. The available evidence supports the use of CPAP
as a first-line treatment for individuals with high AHI and moderate-to-severe sleepiness
associated with obstructive sleep apnea (152). However, it has been reported that CPAP
treatment is effective in improving sleep quality and decreasing symptoms, especially
subjective sleepiness, in subjects with mild OSA (159,160,372-376).
6.2 OSA AND INFLAMMATORY BIOMARKERS
There are only a few publications which have examined the inflammatory biomarkers in
the early stages of OSA. Moreover, there are no publications at all  on the effect of weight
loss on inflammatory markers in OSA.
This present study showed that the inflammatory system is activated in patients with
mild OSA as compared with individuals without OSA. The most important new
information emerging from this  study was that  both anti-inflammatory marker  levels,  IL-
1Ra and IL-10, were elevated in overweight or obese patients with mild OSA. This increase
was higher in those subjects with higher AHI and more severe night-time desaturations.
Successful weight loss therapy resulted in a decrease of the level of IL-1Ra, and the
improving insulin resistance best explained this decrease. These results concerning insulin
metabolism  and  IL-1Ra  are  understandable  because  it  is  known  that  IL-1Ra  levels  are
elevated in those individuals who will later develop diabetes (361), and, on the other hand,
this  cytokine  improves  glycemic  control  in  by  improving  the  IL-1  induced  beta-cell
dysfunction (276,377). In the perspective of OSA patients’ general health, it is also
important that both IL-10 and and IL-1Ra have been shown to have a beneficial effect on
the risk of suffering atherosclerosis and coronary events (275,378-380).
With the respect to the pro-inflammatory cytokines, this investigation supports the
earlier reports of the association between OSA severity and levels of pro-inflammatory
CRP, IL-6 and TNF-, i.e. the pro-inflammatory activation seems to be weaker than that in
more severe disease (6,288,290,291,293,295,296,298,301-303).  In this present study
concentrating on early stages of OSA, there were no significantly elevated levels of CRP or
IL-6 as compared to normal subjects (290,307,310,312). However, even a minimal number of
apnea-hypopnea events seemed to correlate with CRP. This supports the proposal that in
more severe disease with higher AHI, the CRP level is elevated. Moreover, an association
was detected between elevated TNF- and AHI. The lower levels of IL-1 in the group of
sleep apneics compared with the controls may be explained by the simultaneous high
concentration of IL-1Ra, which negatively regulates IL-1 signaling, and IL-10, which
inhibits the production of IL-1. This high activity of the anti-inflammatory biomarkers may
explain the lower concentrations of pro-inflammatory markers in mild OSA as compared to
those encountered in more severe disease.
Weight loss resulted in reductions in CRP and IL-6 concentrations even though there
was no difference between the supervised and traditional lifestyle guidance group. Both of
these biomarkers are known to be associated with obesity and to decrease in response to
weight loss (336,341,342). It has also been proposed that it is the excessive fat and not OSA
per se, which is responsible for the elevation of CRP and IL-6 in overweight patients with
OSA (6,288,307,312,316). However, this present study revealed that in patients with mild
OSA,  the  degree  of  AHI and the  change in  AHI achieved by weight  loss  were  significant
determinants of the CRP levels.
Finally, the interaction of pro- and anti-inflammatory cytokines is complex and
multidirectional. Anti-inflammatory cytokines can inhibit the production (IL-10 inhibits IL-
6 and IL-1) or the effect (IL-1Ra inhibits IL-1) of pro-inflammatory compounds (381,382). In
addition, IL-10 is known to enhance the production of IL-1Ra. In the light of these previous
and the present data, it seems that there is an active ongoing struggle to counteract the pro-
inflammatory processes, and that the body still has capacity to succeed in this effort, even
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in overweight patients with mild OSA and co-morbidities. Moreover, this activation seems
to  vanish  with  weight  loss,  partly  due  to  improvement  of  metabolism  and  partly  due  to
improving night-time breathing. Thus, mild OSA can be considered as a condition similar
to pre-diabetes: patients have same risk factor (obesity), a similar activation of low-grade
inflammation, and lifestyle intervention can stop the evolution to full-blown disease with
its increased risk of serious co-morbidities. On the basis of this study, it seems that obesity,
mild OSA and inflammation are interacting but it is impossible to show the mutual
causality – that would need a larger and better selected population (subjects with no co-
morbidities and also a group of lean subjects).
6.3 CLINICAL ASPECTS
We demonstrated that mild OSA patients experience the disease as being detrimental to
their quality of life, and if left untreated, the disease progresses to become more severe with
time as measured by both AHI and the severity of symptoms. These patients should not be
left  untreated.  Thus,  the  clinical  guidelines  of  American  Academy  of  Sleep  Medicine  for
OSA are very important: the questions regarding OSA should be incorporated into routine
health evaluations, a physician should keep this disease in mind, and if diagnosed, “OSA
should be approached as a chronic disease…” (30).
Largely on the basis of Kuopio sleep apnea study, lifestyle intervention with weight
reduction is now included in the Finnish “Current Care” evidence based treatment
guidelines of OSA in adults, but more effort should certainly be exerted to introduce it in
widespread clinical practice (29). Intensive lifestyle and weight loss program in a group
supervised by a clinical nutritionist could be a good option. This type of first-line treatment
is also recommended for obesity (141).  In Finland, a good way to reach the overweight or
obese individuals could be through the primary health care systems provided by
communities and employers. However, the knowledge about the association of OSA and
comorbidites, and the beneficial effect of weight loss needs to be increased.
Weight loss resulted in improvement of insulin and cholesterol metabolism and also
lowered alanine aminotransferace levels. This is very important, since most OSA patients
are at a high risk of suffering cardiometabolic complications or even already have these
diseases. Thus, all physicians working with these diseases need to be alerted to ask about
snoring, breathing pauses and EDS, and to remember OSA as a possible risk of these
diseases and as a cause of poor treatment results.
This study raises the question of whether an early and successful intervention with
weight loss could normalize the elevated levels of inflammatory cytokines, and whether
this would benefit  the patients in terms of reduced cardiovascular risk, particularly obese
patients with OSA. It is not yet clear, if the up-regulation of anti-inflammatory cytokines in
mild OSA is sufficient to have some protective effect against the cardiometabolic disorders
in patients with OSA. More prospective studies are warranted to assess the prognostic
relevance of these biomarkers in different study populations.
6.4 LIMITATIONS OF THE PRESENT STUDY
The numbers of patients in the present studies were not large, which has also been the case
in most other studies investigating mild OSA. This probably results from the relative
disinterest  in  this  subgroup  of  OSA,  because  more  emphasis  has  been  paid  to  the  more
severe forms of OSA due to the exacerbated symptoms and the more obvious co-morbidity
risk. The problem is statistically exaggerated when patients are divided into smaller
subgroups within a study.
In the retrospective part of the study, those patients who were more symptomatic and/or
dissatisfied with their OSA at the time of inquiry, may have been more likely to complete
the questionnaire and return it. This may have resulted in selection bias.
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The prospective part of this thesis was based on a sub-analysis of an on-going study. The
original intent was to investigate the effect of weight loss on mild OSA and the study was
not specially designed to analyze the changes in inflammatory biomarkers. The number of
patients was reduced because of unsuccessful biomarker analysis. However, this is the first
study in this field and thus will serve as a good reference for further studies. Although the
results regarding the changes in inflammatory mediators are novel especially in terms of
the anti-inflammatory compounds, they need to be replicated in larger studies, and by
examining healthy normal weight patients with mild OSA to quantify the true impact of the
disease on these changes. Furthermore, a longer follow-up time of one year would give
more reliable objective outcome information on the sustainability of reduced weight and
improved OSA.
The diagnosis of OSA was based on overnight in-home cardio-respiratory recording.
This limits the further analysis on how the symptoms and inflammatory markers relate to
sleep structure, for example to the arousal index. Night-to-night variability in AHI can play
a role in the findings of study. However, in the home environment, one night testing has
been shown to be reliable (383).
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7 Conclusions
The findings of the present study were
1. Mild OSA has a natural tendency to worsen with time. Active treatment can prevent
progression of the disease.  (Study I).
2. Obstructive sleep apnea patients experience symptoms detrimental to quality of
their life. If left untreated, both night-time and daytime symptoms become worse.
Upper airway surgery may be a good treatment option in selected cases. (Study II).
3. There is an activation not only of pro-inflammatory biomarkers but also anti-
inflammatory compounds in overweight patients with mild OSA.  Hypoxemia seems
to have an effect on the concentrations of these biologically active compounds.
(Study III).
4. In overweight patients with mild OSA, lifestyle intervention with weight reduction
results in improvement of low-grade inflammation. (Study IV).
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Appendices
1. Retrospective data
2. The follow-up of obstructive sleep apnea patients in Kuopio University Hospital
3. The effect of weight loss and lifestyle guidance on obstructive sleep apnea

THE FOLLOW-UP OF OBSTRUCTIVE SLEEP APNEA PATIENTS IN KUOPIO UNIVERSITY HOSPITAL
NAME Tel.
DATE OF BIRTH Date
Height: Weight:
Please circle the most appropriate option
1. How many hours do you sleep per night?
1. 6 h or less 2. 6-8 h 3. more than 8 h
2. Has somebody told you to have breathing pauses when asleep?
1. No 3. Don’t know 5. Always
2. Sometimes 4. Often
3. Are you tired during daytime?
1. Always 3. Don’t know 5. No
2. Sometimes 4. rarely
4. Do you take a nap?
1. No 2. Yes
5. Are you more tired than your friends or co-workers during daytime?
1. No, much more awake than they are 4. Yes, more tired than they are
2. No, more awake than they are 5. yes, much more tired than they are
3. No difference
6. Have you ever fallen asleep when driving a vehicle?
1. Never 3. Twice 5. At least 5 times
2. Yes, once 4. 3-4 times
7. Have you ever been in an accident due to tiredness?
1. Never 3. Twice 5. At least 5 times
2. Yes, once 4. 3-4 times
8. Do you easily fall asleep at a lesson, or while watching a movie/TV etc.
1. Always 3. Sometimes 5. Never
2. Often 4. Rarely
9. Have you ever had complaints about your tiredness at school or at work?
1. No 2. yes
10. How soon do you fell asleep when going to bed in the evening?
1. In 10 min or faster 2. 10-30 min 3. more than 30 min
11. How do you sleep?
1. Very restless 3. Don’t know 5. Very calm
2. Restless 4. Calm
12. How many times do you wake up during a night?
1. Not at all 3. Twice 5. Five times or more
2. Once 4. 3-4 times
13. In the last three months, have you had insomnia?
1. Almost every night 3. Sometimes 5. Never
2. Often 4. Seldom
14. Do you feel refreshed when you wake up in the morning?
1. Yes, very 3. Don’t know 5. I feel extremely tired
2. To some extent 4. I feel tired
15. How often have you had these symptoms during night-time in the last years. Cross the appropriate choice.
Always Often Sometimes Never Don’t know
a Snoring
b Teeth biting
c Urge to urinate
d Nightmares
e Sleepwalking/talking
f Sweating during night
g Choking
16. Do you snore?
1. I don’t snore 3. Most of the sleeping-time
2. Rarely/ in certain positions 4. All the time and loudly
17. Have you taken sleeping pills during the last three months?
1. Never 3. Sometimes 5. Regularly
2. Rarely 4. Often
18. How much do you drink alcohol? (Days per week or month. How much?)_____________________
_______________________________________________________________________________________
19. Do you smoke?
1. Never 3. Yes, 1-5 cigarettes/day 5. 11-20 /day
2. Ex-xmoker 4. 6-10 /day 6. More than 20/day
20. Have you had the following symptoms? Cross the appropriate choice.
I have now I have had Never Don’t know
a Morning headache
b Difficult to concentrate
c Nervousness
d Irritability
e Impotence
f Decreased libido
g High blood pressure
h Depression
i Coronary artery disease
j Heart attack
k Cerebrovascular disease
l Pulmonary diseases
21.  Other medical conditions 1. No 2.Yes_____________________________________________
_________________________________________________________________________________________
22. Medication____________________________________________________________________________
23.    Shift work 1. No 2. yes
24. What kind of treatment have you had for sleep apnea? You may circle several choices if needed.
1. No treatment 5. I had an operation
2. Lifestyle guidance by a doctor 6. I have CPAP
3. Lifestyle guidance by a nutritionist 7. Something else________________________________
4. Positional treratment
25. If you have had an operation due to sleep apnea are you
1.      Satisfied 2. Dissatisfied with the result
26.    If you have (had) CPAP are you
1.      Satisfied 2. Dissatisfied             3. Dissatisfied and terminated the use
27.    Have you ever tried to lose weight due to sleep apnea?
                  1.      No 2. Yes, but I regain the weight 3. Yes and I remain at the lower weight
28.    How do you see your sleep apnea symptoms at the moment compared to your last visit to the ENT-department or before treatment?
Snoring 1. decreased a lot 4. increased a little bit
2. decreased a little bit 5. increased a lot
3. remained the same 6. don’t know
Breathing pauses 1. decreased a lot 4. increased a little bit
2. decreased a little bit 5. increased a lot
3. remained the same 6. don’t know
Daytime sleepiness 1. decreased a lot 4. increased a little bit
2. decreased a little bit 5. increased a lot
3. remained the same 6. don’t know
THANK YOU FOR YOUR CONTRIBUTION!
Note! The questions 23-28 were asked only at the follow-up.
PATIENT DATA Baseline/12 months Patient nr. _________
THE EFFECT OF WEIGHT LOSS AND LIFESTYLE GUIDANCE ON OBSTRUCTIVE SLEEP APNEA
NAME: Tel.
Sex:___________________ Height:___________________ Weight:_________________________
Smoking 1. No 2. Yes
How much do you drink alcohol? How many days per week/month and how much?________________________
____________________________________________________________________________________________________
Medical conditions___________________________________________________________________________________
____________________________________________________________________________________________________
Medication__________________________________________________________________________________________
____________________________________________________________________________________________________
In the past 4 weeks,  when you have been asleep, to the best of your knowledge do you snore?
1. All of the time 3. Some of the time 5. None of the time
2. Most of the time 4.A little of the time 6. Don’t know
In the past 4 weeks, how would you describe your snoring or how has it been described to you?
1. None 3. Moderate 5. Very severe
2. Mild 4. Severe 6. Don’t know
My snoring wakes me from sleep and/or makes me tired the next day
1. Definitely true 3. Don’t know 5. Definitely false
2. Somewhat true 4. False
During the past 4 weeks, how much did your snoring interfere with your normal sleep and your level of energy?
1. Not at all 3. Moderately 5. Extremely
2. A little bit 4.Quite a bit
Does your snoring annoy or bother your spouse/bed partner?
1. Extremely 3. Moderately 5. Not. at all
2. Quite a bit 4. A little bit 6. Don’t know
Compared to one year ago, how would you rate your snoring now?
1. Much less 3. About the same 5. Much more than a year ago
2. Somewhat less 4. Somewhat more
How would your spouse/bed partner describe your snoring?
1. Extremely loud 3. Somewhat loud 5. No snoring at all
2. Very loud 4. Soft and quiet 6. Don’t know
Please describe when you snore?
1. I don’t snore 3. Only in certain positions 5. I snore all of the time
2. I snore very rarely 4. I snore most of the time
Have someone told you that you have breathing pauses when you sleep?
1. No 3. I don’t know 5. Always
2. Sometimes 4. Often
Do you nap? 1. No 2. Yes
How long does it take t  fall asleep in the evening?
1. Max. 10 minutes 2. 10-30 min 3. more than 30 minutes
o
How do you sleep at night?
1. Very restless 3. Don’t know 5. Very calm
2. Restless 4. Calm
How many times do you wake up during the night?
1. Not at all 3. Twice 5. At least five times
2. Once 4. 3-4 times
In last three months, have you had insomnia ?
1. Almost every night 3. Sometimes 5. Never
2. Often 4. Rarely
Do you feel refreshed when you wake up in the morning?
1. Yes, very 3. Don’t know 5. I feel extremely tired
2. To some extend 4. I feel tired
Do you have headache in the morning?
1. Never 3. Sometimes 5. Regularly
2. Rarely 4. Often
In last three months, have you used sleeping pills?
1. Never 3. Sometimes 5. Regularly
2. Rarely 4. Often
Have you ever fallen asleep when driving a vehicle?
1. Never 3. Twice 5. At least five times
2. Yes, once 4. 3-4 times
Have you ever had a traffic accident due to tiredness?
1. Never 3. Twice 5. At least five times
2. Yes, once 4. 3-4 times
Has your working ability been decreased?
During last three months? During last year?
1. Yes, ________days 1. Yes,_________days
2. No 2. No
How likely do you doze off or fall asleep in the following situations? Choose the most appropriate number.
Change of dozing
Situation No change Slight change Moderate High change
change
Sitting and reading       0       1       2       3
Watching TV       0       1       2       3
Sitting inactive in a public place
(e.g.a theater or a meeting)       0       1       2       3
As a passenger in a car for an
hour without a break       0       1       2       3
Lying down to rest in the after-
noon when circumstances permit            0       1       2       3
Sitting and talking to someone       0       1       2       3
Sitting quietly after a lunch
without alcohol       0       1       2       3
In a car, while stopped for
a few minutes in traffic       0       1       2       3
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Obstructive sleep apnea (OSA) causes 
both daytime and night-time symptoms 
for the patient; in particular the more 
severe forms of OSA are also associated 
with an increased risk of cardiovascu-
lar and metabolic diseases. This thesis 
examines the evolution of mild OSA. The 
activation of low-grade inflammation, 
which is one of the mechanisms lead-
ing to abovementioned co-morbidities, 
as well as the effect of weight loss on 
inflammation are clarified in overweight 
patients with mild OSA. This study dem-
onstrated that even mild OSA should be 
actively treated to prevent progression of 
the disease. Moreover, low-grade inflam-
mation was found to be activated already 
in early stages of disease. Weight loss 
was a useful way to decrease the inflam-
matory burden.
 
